{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 105,
   "source": [
    "import requests\r\n",
    "import pandas as pd\r\n",
    "import regex as re\r\n",
    "import os\r\n",
    "from dotenv import load_dotenv\r\n",
    "import matplotlib.pyplot as plt\r\n",
    "\r\n",
    "from nltk.corpus import stopwords, reuters\r\n",
    "from nltk.tokenize import word_tokenize\r\n",
    "from nltk.stem import WordNetLemmatizer\r\n",
    "from wordcloud import WordCloud\r\n",
    "\r\n",
    "load_dotenv()"
   ],
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "metadata": {},
     "execution_count": 105
    }
   ],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "source": [
    "def clean_tokenize(raw_text):\r\n",
    "    lemmatizer = WordNetLemmatizer()\r\n",
    "    cleanr = re.compile('\\.+|<.*?>|&([a-z0-9]+|#[0-9]{1,6}|#x[0-9a-f]{1,6});')\r\n",
    "    cleantext = re.sub(cleanr, '', raw_text).replace('\\r', ' ').replace('\\t', ' ').replace('\\n', ' ').strip()\r\n",
    "    new_content = ' '.join(cleantext.split())\r\n",
    "    sw = set(stopwords.words('english'))\r\n",
    "    regex = re.compile(\"[^a-zA-Z ]\")\r\n",
    "    re_clean = regex.sub('', new_content)\r\n",
    "    words = word_tokenize(re_clean)\r\n",
    "    lem = [lemmatizer.lemmatize(word) for word in words]\r\n",
    "    output = [word.lower() for word in lem if word.lower() not in sw]\r\n",
    "    return ' '.join(output)"
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "source": [
    "def get_news(tickers, range_of_dates):\r\n",
    "    news_df = pd.DataFrame()\r\n",
    "    ticker_string = ','.join(tickers)\r\n",
    "    for date in range_of_dates:\r\n",
    "        url = f'https://api.benzinga.com/api/v2/news?token=6b65009cb3594ca380ef509da6e1deee&date={str(date.date())}&tickers={ticker_string}&displayOutput=full'\r\n",
    "        data = requests.get(url, headers={'accept': 'application/json'})\r\n",
    "        news_df = news_df.append(data.json())\r\n",
    "    news_df = news_df.drop(['id', 'author', 'updated', 'teaser', 'url', 'image', 'channels', 'tags'], axis=1)\r\n",
    "    news_df['created'] = pd.to_datetime(pd.to_datetime(news_df['created']).dt.date).dt.normalize()\r\n",
    "    news_df = news_df.rename(columns={'created': 'date'})\r\n",
    "    return news_df\r\n",
    "    "
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "source": [
    "news_df = get_news(['AZN', 'JNJ', 'PFE', 'MRNA'], pd.date_range('2020-09-01', '2021-09-15'))\r\n",
    "news_df['word_tokens'] = news_df['body'].apply(clean_tokenize)\r\n",
    "news_df['word_tokens'] += news_df['title'].apply(clean_tokenize)\r\n"
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "source": [
    "def assign_ticker(x):\r\n",
    "    if 'AZN' in  [value for elem in x for value in elem.values()]:\r\n",
    "        return 'AZN'\r\n",
    "    if 'MRNA' in  [value for elem in x for value in elem.values()]:\r\n",
    "        return 'MRNA'\r\n",
    "    if 'JNJ' in  [value for elem in x for value in elem.values()]:\r\n",
    "        return 'JNJ'\r\n",
    "    if 'PFE' in  [value for elem in x for value in elem.values()]:\r\n",
    "        return 'PFE'\r\n",
    "\r\n",
    "news_df['symbol'] = news_df['stocks'].apply(assign_ticker)"
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "source": [
    "news_df"
   ],
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>date</th>\n",
       "      <th>title</th>\n",
       "      <th>body</th>\n",
       "      <th>stocks</th>\n",
       "      <th>word_tokens</th>\n",
       "      <th>symbol</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2020-09-16</td>\n",
       "      <td>AstraZeneca Trial Participant Adverse Events L...</td>\n",
       "      <td>&lt;p&gt;&lt;strong&gt;AstraZeneca Plc&amp;rsquo;s &lt;/strong&gt;(N...</td>\n",
       "      <td>[{'name': 'AZN'}, {'name': 'MRNA'}, {'name': '...</td>\n",
       "      <td>astrazeneca plcs nyseazn vaccine didnt likely ...</td>\n",
       "      <td>AZN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2020-09-17</td>\n",
       "      <td>Sinovac Plans To Expand COVID-19 Vaccine Trial...</td>\n",
       "      <td>&lt;p&gt;&lt;strong&gt;Sinovac Biotech&lt;/strong&gt; has plans ...</td>\n",
       "      <td>[{'name': 'AZN'}, {'name': 'BNTX'}, {'name': '...</td>\n",
       "      <td>sinovac biotech ha plan expand clinical trial ...</td>\n",
       "      <td>AZN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2020-09-17</td>\n",
       "      <td>5 Stocks To Watch For September 17, 2020</td>\n",
       "      <td>&lt;p&gt;Some of the stocks that may grab investor f...</td>\n",
       "      <td>[{'name': 'APOG'}, {'name': 'CHWY'}, {'name': ...</td>\n",
       "      <td>stock may grab investor focus today wall stree...</td>\n",
       "      <td>MRNA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2020-09-17</td>\n",
       "      <td>BioNTech Buys German Biotech Production Site f...</td>\n",
       "      <td>BioNTech SE (NASDAQ:&lt;a class=\"ticker\" href=\"/s...</td>\n",
       "      <td>[{'name': 'BNTX'}, {'name': 'NVS'}, {'name': '...</td>\n",
       "      <td>biontech se nasdaqbntx today announced signing...</td>\n",
       "      <td>PFE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2020-09-17</td>\n",
       "      <td>AstraZeneca Acquires Oral PCSK9 Inhibitor Prog...</td>\n",
       "      <td>AstraZeneca (NYSE:&lt;a class=\"ticker\" href=\"/sto...</td>\n",
       "      <td>[{'name': 'AZN'}]</td>\n",
       "      <td>astrazeneca nyseazn ha entered agreement dogma...</td>\n",
       "      <td>AZN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>2021-09-15</td>\n",
       "      <td>FDA Declines To Take Stance On Pfizer's COVID-...</td>\n",
       "      <td>&lt;p&gt;-Reuters&lt;/p&gt;</td>\n",
       "      <td>[{'name': 'BNTX'}, {'name': 'PFE'}]</td>\n",
       "      <td>reutersfda declines take stance pfizers covid ...</td>\n",
       "      <td>PFE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>2021-09-15</td>\n",
       "      <td>Pfizer Builds Case For COVID-19 Booster As Pro...</td>\n",
       "      <td>&lt;ul&gt;\\r\\n\\t&lt;li&gt;&lt;strong&gt;Pfizer Inc&lt;/strong&gt;&amp;nbsp...</td>\n",
       "      <td>[{'name': 'BNTX'}, {'name': 'PFE'}]</td>\n",
       "      <td>pfizer incnysepfe said us regulator approve bo...</td>\n",
       "      <td>PFE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>2021-09-15</td>\n",
       "      <td>Moderna Highlights New Clinical Data On COVID-...</td>\n",
       "      <td>&lt;h1&gt;Moderna Highlights New Clinical Data on it...</td>\n",
       "      <td>[{'name': 'MRNA'}]</td>\n",
       "      <td>moderna highlights new clinical data covid vac...</td>\n",
       "      <td>MRNA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>2021-09-15</td>\n",
       "      <td>UPDATE: Moderna Says 'mRNA-1273 remains highly...</td>\n",
       "      <td></td>\n",
       "      <td>[{'name': 'MRNA'}]</td>\n",
       "      <td>update moderna says mrna remains highly effect...</td>\n",
       "      <td>MRNA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>2021-09-15</td>\n",
       "      <td>UPDATE: Moderna Says 'New analysis of open-lab...</td>\n",
       "      <td></td>\n",
       "      <td>[{'name': 'MRNA'}]</td>\n",
       "      <td>update moderna says new analysis openlabel por...</td>\n",
       "      <td>MRNA</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3670 rows Ã— 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         date                                              title  \\\n",
       "0  2020-09-16  AstraZeneca Trial Participant Adverse Events L...   \n",
       "1  2020-09-17  Sinovac Plans To Expand COVID-19 Vaccine Trial...   \n",
       "2  2020-09-17           5 Stocks To Watch For September 17, 2020   \n",
       "3  2020-09-17  BioNTech Buys German Biotech Production Site f...   \n",
       "4  2020-09-17  AstraZeneca Acquires Oral PCSK9 Inhibitor Prog...   \n",
       "..        ...                                                ...   \n",
       "10 2021-09-15  FDA Declines To Take Stance On Pfizer's COVID-...   \n",
       "11 2021-09-15  Pfizer Builds Case For COVID-19 Booster As Pro...   \n",
       "12 2021-09-15  Moderna Highlights New Clinical Data On COVID-...   \n",
       "13 2021-09-15  UPDATE: Moderna Says 'mRNA-1273 remains highly...   \n",
       "14 2021-09-15  UPDATE: Moderna Says 'New analysis of open-lab...   \n",
       "\n",
       "                                                 body  \\\n",
       "0   <p><strong>AstraZeneca Plc&rsquo;s </strong>(N...   \n",
       "1   <p><strong>Sinovac Biotech</strong> has plans ...   \n",
       "2   <p>Some of the stocks that may grab investor f...   \n",
       "3   BioNTech SE (NASDAQ:<a class=\"ticker\" href=\"/s...   \n",
       "4   AstraZeneca (NYSE:<a class=\"ticker\" href=\"/sto...   \n",
       "..                                                ...   \n",
       "10                                    <p>-Reuters</p>   \n",
       "11  <ul>\\r\\n\\t<li><strong>Pfizer Inc</strong>&nbsp...   \n",
       "12  <h1>Moderna Highlights New Clinical Data on it...   \n",
       "13                                                      \n",
       "14                                                      \n",
       "\n",
       "                                               stocks  \\\n",
       "0   [{'name': 'AZN'}, {'name': 'MRNA'}, {'name': '...   \n",
       "1   [{'name': 'AZN'}, {'name': 'BNTX'}, {'name': '...   \n",
       "2   [{'name': 'APOG'}, {'name': 'CHWY'}, {'name': ...   \n",
       "3   [{'name': 'BNTX'}, {'name': 'NVS'}, {'name': '...   \n",
       "4                                   [{'name': 'AZN'}]   \n",
       "..                                                ...   \n",
       "10                [{'name': 'BNTX'}, {'name': 'PFE'}]   \n",
       "11                [{'name': 'BNTX'}, {'name': 'PFE'}]   \n",
       "12                                 [{'name': 'MRNA'}]   \n",
       "13                                 [{'name': 'MRNA'}]   \n",
       "14                                 [{'name': 'MRNA'}]   \n",
       "\n",
       "                                          word_tokens symbol  \n",
       "0   astrazeneca plcs nyseazn vaccine didnt likely ...    AZN  \n",
       "1   sinovac biotech ha plan expand clinical trial ...    AZN  \n",
       "2   stock may grab investor focus today wall stree...   MRNA  \n",
       "3   biontech se nasdaqbntx today announced signing...    PFE  \n",
       "4   astrazeneca nyseazn ha entered agreement dogma...    AZN  \n",
       "..                                                ...    ...  \n",
       "10  reutersfda declines take stance pfizers covid ...    PFE  \n",
       "11  pfizer incnysepfe said us regulator approve bo...    PFE  \n",
       "12  moderna highlights new clinical data covid vac...   MRNA  \n",
       "13  update moderna says mrna remains highly effect...   MRNA  \n",
       "14  update moderna says new analysis openlabel por...   MRNA  \n",
       "\n",
       "[3670 rows x 6 columns]"
      ]
     },
     "metadata": {},
     "execution_count": 110
    }
   ],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "source": [
    "big_string = ' '.join(news_df['word_tokens'].values)\r\n",
    "wc = WordCloud().generate(big_string)\r\n",
    "plt.imshow(wc)"
   ],
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "<matplotlib.image.AxesImage at 0x1b556afab48>"
      ]
     },
     "metadata": {},
     "execution_count": 111
    }
   ],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "source": [
    "from collections import Counter\r\n",
    "from nltk import ngrams"
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "source": [
    "news_bigrams = ngrams([word for value in news_df['word_tokens'].values for word in value.split()], n=2)\r\n",
    "list(news_bigrams)"
   ],
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[('astrazeneca', 'plcs'),\n",
       " ('plcs', 'nyseazn'),\n",
       " ('nyseazn', 'vaccine'),\n",
       " ('vaccine', 'didnt'),\n",
       " ('didnt', 'likely'),\n",
       " ('likely', 'cause'),\n",
       " ('cause', 'adverse'),\n",
       " ('adverse', 'event'),\n",
       " ('event', 'suspended'),\n",
       " ('suspended', 'latestage'),\n",
       " ('latestage', 'human'),\n",
       " ('human', 'trial'),\n",
       " ('trial', 'drug'),\n",
       " ('drug', 'according'),\n",
       " ('according', 'oxford'),\n",
       " ('oxford', 'university'),\n",
       " ('university', 'happened'),\n",
       " ('happened', 'volunteers'),\n",
       " ('volunteers', 'british'),\n",
       " ('british', 'drugmakers'),\n",
       " ('drugmakers', 'chadox'),\n",
       " ('chadox', 'ncov'),\n",
       " ('ncov', 'vaccine'),\n",
       " ('vaccine', 'trial'),\n",
       " ('trial', 'developed'),\n",
       " ('developed', 'unexplained'),\n",
       " ('unexplained', 'neurological'),\n",
       " ('neurological', 'symptom'),\n",
       " ('symptom', 'including'),\n",
       " ('including', 'changed'),\n",
       " ('changed', 'sensation'),\n",
       " ('sensation', 'weakness'),\n",
       " ('weakness', 'limb'),\n",
       " ('limb', 'according'),\n",
       " ('according', 'participant'),\n",
       " ('participant', 'information'),\n",
       " ('information', 'document'),\n",
       " ('document', 'published'),\n",
       " ('published', 'oxford'),\n",
       " ('oxford', 'codeveloping'),\n",
       " ('codeveloping', 'vaccine'),\n",
       " ('vaccine', 'astrazeneca'),\n",
       " ('astrazeneca', 'independent'),\n",
       " ('independent', 'review'),\n",
       " ('review', 'illness'),\n",
       " ('illness', 'either'),\n",
       " ('either', 'considered'),\n",
       " ('considered', 'unlikely'),\n",
       " ('unlikely', 'associated'),\n",
       " ('associated', 'vaccine'),\n",
       " ('vaccine', 'wa'),\n",
       " ('wa', 'insufficient'),\n",
       " ('insufficient', 'evidence'),\n",
       " ('evidence', 'say'),\n",
       " ('say', 'certain'),\n",
       " ('certain', 'illness'),\n",
       " ('illness', 'related'),\n",
       " ('related', 'vaccine'),\n",
       " ('vaccine', 'oxford'),\n",
       " ('oxford', 'said'),\n",
       " ('said', 'first'),\n",
       " ('first', 'reported'),\n",
       " ('reported', 'reuters'),\n",
       " ('reuters', 'independent'),\n",
       " ('independent', 'reviewer'),\n",
       " ('reviewer', 'recommended'),\n",
       " ('recommended', 'vaccination'),\n",
       " ('vaccination', 'continue'),\n",
       " ('continue', 'reviewing'),\n",
       " ('reviewing', 'case'),\n",
       " ('case', 'according'),\n",
       " ('according', 'document'),\n",
       " ('document', 'matters'),\n",
       " ('matters', 'astrazeneca'),\n",
       " ('astrazeneca', 'ha'),\n",
       " ('ha', 'resumed'),\n",
       " ('resumed', 'trial'),\n",
       " ('trial', 'vaccine'),\n",
       " ('vaccine', 'united'),\n",
       " ('united', 'kingdom'),\n",
       " ('kingdom', 'india'),\n",
       " ('india', 'south'),\n",
       " ('south', 'africa'),\n",
       " ('africa', 'brazil'),\n",
       " ('brazil', 'trials'),\n",
       " ('trials', 'havent'),\n",
       " ('havent', 'yet'),\n",
       " ('yet', 'resumed'),\n",
       " ('resumed', 'united'),\n",
       " ('united', 'states'),\n",
       " ('states', 'food'),\n",
       " ('food', 'drug'),\n",
       " ('drug', 'administration'),\n",
       " ('administration', 'commissioner'),\n",
       " ('commissioner', 'stephen'),\n",
       " ('stephen', 'hahn'),\n",
       " ('hahn', 'said'),\n",
       " ('said', 'agency'),\n",
       " ('agency', 'going'),\n",
       " ('going', 'significant'),\n",
       " ('significant', 'work'),\n",
       " ('work', 'company'),\n",
       " ('company', 'figure'),\n",
       " ('figure', 'significant'),\n",
       " ('significant', 'safety'),\n",
       " ('safety', 'issue'),\n",
       " ('issue', 'moderna'),\n",
       " ('moderna', 'inc'),\n",
       " ('inc', 'nysemrna'),\n",
       " ('nysemrna', 'pfizer'),\n",
       " ('pfizer', 'inc'),\n",
       " ('inc', 'nysepfe'),\n",
       " ('nysepfe', 'likely'),\n",
       " ('likely', 'frontrunners'),\n",
       " ('frontrunners', 'race'),\n",
       " ('race', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'microsoft'),\n",
       " ('microsoft', 'corporation'),\n",
       " ('corporation', 'nasdaqmsft'),\n",
       " ('nasdaqmsft', 'cofounder'),\n",
       " ('cofounder', 'bill'),\n",
       " ('bill', 'gates'),\n",
       " ('gates', 'claimed'),\n",
       " ('claimed', 'pfizers'),\n",
       " ('pfizers', 'vaccine'),\n",
       " ('vaccine', 'may'),\n",
       " ('may', 'get'),\n",
       " ('get', 'emergency'),\n",
       " ('emergency', 'use'),\n",
       " ('use', 'license'),\n",
       " ('license', 'end'),\n",
       " ('end', 'october'),\n",
       " ('october', 'according'),\n",
       " ('according', 'cnbc'),\n",
       " ('cnbc', 'price'),\n",
       " ('price', 'action'),\n",
       " ('action', 'astrazeneca'),\n",
       " ('astrazeneca', 'share'),\n",
       " ('share', 'closed'),\n",
       " ('closed', 'almost'),\n",
       " ('almost', 'lower'),\n",
       " ('lower', 'wednesday'),\n",
       " ('wednesday', 'gained'),\n",
       " ('gained', 'afterhours'),\n",
       " ('afterhours', 'sessionastrazeneca'),\n",
       " ('sessionastrazeneca', 'trial'),\n",
       " ('trial', 'participant'),\n",
       " ('participant', 'adverse'),\n",
       " ('adverse', 'events'),\n",
       " ('events', 'likely'),\n",
       " ('likely', 'unrelated'),\n",
       " ('unrelated', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'oxford'),\n",
       " ('oxford', 'sinovac'),\n",
       " ('sinovac', 'biotech'),\n",
       " ('biotech', 'ha'),\n",
       " ('ha', 'plan'),\n",
       " ('plan', 'expand'),\n",
       " ('expand', 'clinical'),\n",
       " ('clinical', 'trial'),\n",
       " ('trial', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'trial'),\n",
       " ('trial', 'child'),\n",
       " ('child', 'adolescent'),\n",
       " ('adolescent', 'later'),\n",
       " ('later', 'month'),\n",
       " ('month', 'happened'),\n",
       " ('happened', 'chinese'),\n",
       " ('chinese', 'vaccine'),\n",
       " ('vaccine', 'maker'),\n",
       " ('maker', 'hope'),\n",
       " ('hope', 'carry'),\n",
       " ('carry', 'study'),\n",
       " ('study', 'healthy'),\n",
       " ('healthy', 'participant'),\n",
       " ('participant', 'ranging'),\n",
       " ('ranging', 'age'),\n",
       " ('age', 'three'),\n",
       " ('three', 'according'),\n",
       " ('according', 'information'),\n",
       " ('information', 'company'),\n",
       " ('company', 'filed'),\n",
       " ('filed', 'national'),\n",
       " ('national', 'library'),\n",
       " ('library', 'medicine'),\n",
       " ('medicine', 'combined'),\n",
       " ('combined', 'phase'),\n",
       " ('phase', 'phase'),\n",
       " ('phase', 'trial'),\n",
       " ('trial', 'take'),\n",
       " ('take', 'place'),\n",
       " ('place', 'chinas'),\n",
       " ('chinas', 'hebei'),\n",
       " ('hebei', 'province'),\n",
       " ('province', 'commence'),\n",
       " ('commence', 'sept'),\n",
       " ('sept', 'company'),\n",
       " ('company', 'said'),\n",
       " ('said', 'asfirst'),\n",
       " ('asfirst', 'noticed'),\n",
       " ('noticed', 'reuters'),\n",
       " ('reuters', 'drugmaker'),\n",
       " ('drugmaker', 'said'),\n",
       " ('said', 'volunteer'),\n",
       " ('volunteer', 'would'),\n",
       " ('would', 'given'),\n",
       " ('given', 'two'),\n",
       " ('two', 'dos'),\n",
       " ('dos', 'drugmakers'),\n",
       " ('drugmakers', 'coronavac'),\n",
       " ('coronavac', 'vaccineor'),\n",
       " ('vaccineor', 'alternatively'),\n",
       " ('alternatively', 'placebo'),\n",
       " ('placebo', 'trial'),\n",
       " ('trial', 'ha'),\n",
       " ('ha', 'already'),\n",
       " ('already', 'approved'),\n",
       " ('approved', 'chinas'),\n",
       " ('chinas', 'regulator'),\n",
       " ('regulator', 'sinovac'),\n",
       " ('sinovac', 'spokesperson'),\n",
       " ('spokesperson', 'told'),\n",
       " ('told', 'reuters'),\n",
       " ('reuters', 'matters'),\n",
       " ('matters', 'vaccine'),\n",
       " ('vaccine', 'work'),\n",
       " ('work', 'entire'),\n",
       " ('entire', 'population'),\n",
       " ('population', 'important'),\n",
       " ('important', 'covid'),\n",
       " ('covid', 'spread'),\n",
       " ('spread', 'adult'),\n",
       " ('adult', 'school'),\n",
       " ('school', 'kindergarten'),\n",
       " ('kindergarten', 'reuters'),\n",
       " ('reuters', 'noted'),\n",
       " ('noted', 'pfizer'),\n",
       " ('pfizer', 'inc'),\n",
       " ('inc', 'nysepfe'),\n",
       " ('nysepfe', 'german'),\n",
       " ('german', 'partner'),\n",
       " ('partner', 'biontech'),\n",
       " ('biontech', 'se'),\n",
       " ('se', 'nasdaqbntx'),\n",
       " ('nasdaqbntx', 'seeking'),\n",
       " ('seeking', 'approval'),\n",
       " ('approval', 'united'),\n",
       " ('united', 'states'),\n",
       " ('states', 'food'),\n",
       " ('food', 'drug'),\n",
       " ('drug', 'administration'),\n",
       " ('administration', 'expand'),\n",
       " ('expand', 'drug'),\n",
       " ('drug', 'trial'),\n",
       " ('trial', 'including'),\n",
       " ('including', 'adolescent'),\n",
       " ('adolescent', 'young'),\n",
       " ('young', 'year'),\n",
       " ('year', 'old'),\n",
       " ('old', 'pfizer'),\n",
       " ('pfizer', 'moderna'),\n",
       " ('moderna', 'inc'),\n",
       " ('inc', 'nasdaqmrna'),\n",
       " ('nasdaqmrna', 'vaccine'),\n",
       " ('vaccine', 'likely'),\n",
       " ('likely', 'distributed'),\n",
       " ('distributed', 'health'),\n",
       " ('health', 'care'),\n",
       " ('care', 'worker'),\n",
       " ('worker', 'highrisk'),\n",
       " ('highrisk', 'group'),\n",
       " ('group', 'late'),\n",
       " ('late', 'october'),\n",
       " ('october', 'early'),\n",
       " ('early', 'november'),\n",
       " ('november', 'according'),\n",
       " ('according', 'new'),\n",
       " ('new', 'york'),\n",
       " ('york', 'times'),\n",
       " ('times', 'oxford'),\n",
       " ('oxford', 'university'),\n",
       " ('university', 'said'),\n",
       " ('said', 'partner'),\n",
       " ('partner', 'astrazeneca'),\n",
       " ('astrazeneca', 'plcs'),\n",
       " ('plcs', 'nyseazn'),\n",
       " ('nyseazn', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'wasntthe'),\n",
       " ('wasntthe', 'likely'),\n",
       " ('likely', 'cause'),\n",
       " ('cause', 'neurological'),\n",
       " ('neurological', 'symptom'),\n",
       " ('symptom', 'weakness'),\n",
       " ('weakness', 'limb'),\n",
       " ('limb', 'latestage'),\n",
       " ('latestage', 'trial'),\n",
       " ('trial', 'participant'),\n",
       " ('participant', 'british'),\n",
       " ('british', 'drugmaker'),\n",
       " ('drugmaker', 'ha'),\n",
       " ('ha', 'resumed'),\n",
       " ('resumed', 'latestage'),\n",
       " ('latestage', 'trial'),\n",
       " ('trial', 'united'),\n",
       " ('united', 'kingdom'),\n",
       " ('kingdom', 'india'),\n",
       " ('india', 'brazil'),\n",
       " ('brazil', 'south'),\n",
       " ('south', 'africa'),\n",
       " ('africa', 'halted'),\n",
       " ('halted', 'due'),\n",
       " ('due', 'reported'),\n",
       " ('reported', 'adverse'),\n",
       " ('adverse', 'event'),\n",
       " ('event', 'earliersinovac'),\n",
       " ('earliersinovac', 'plans'),\n",
       " ('plans', 'expand'),\n",
       " ('expand', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'trials'),\n",
       " ('trials', 'children'),\n",
       " ('children', 'adolescents'),\n",
       " ('adolescents', 'stock'),\n",
       " ('stock', 'may'),\n",
       " ('may', 'grab'),\n",
       " ('grab', 'investor'),\n",
       " ('investor', 'focus'),\n",
       " ('focus', 'today'),\n",
       " ('today', 'wall'),\n",
       " ('wall', 'street'),\n",
       " ('street', 'expects'),\n",
       " ('expects', 'apogee'),\n",
       " ('apogee', 'enterprises'),\n",
       " ('enterprises', 'inc'),\n",
       " ('inc', 'nasdaqapog'),\n",
       " ('nasdaqapog', 'report'),\n",
       " ('report', 'quarterly'),\n",
       " ('quarterly', 'earnings'),\n",
       " ('earnings', 'per'),\n",
       " ('per', 'share'),\n",
       " ('share', 'revenue'),\n",
       " ('revenue', 'million'),\n",
       " ('million', 'opening'),\n",
       " ('opening', 'bell'),\n",
       " ('bell', 'apogee'),\n",
       " ('apogee', 'share'),\n",
       " ('share', 'slipped'),\n",
       " ('slipped', 'afterhours'),\n",
       " ('afterhours', 'trading'),\n",
       " ('trading', 'herman'),\n",
       " ('herman', 'miller'),\n",
       " ('miller', 'inc'),\n",
       " ('inc', 'nasdaqmlhr'),\n",
       " ('nasdaqmlhr', 'reported'),\n",
       " ('reported', 'strong'),\n",
       " ('strong', 'rise'),\n",
       " ('rise', 'earnings'),\n",
       " ('earnings', 'fiscal'),\n",
       " ('fiscal', 'first'),\n",
       " ('first', 'quarter'),\n",
       " ('quarter', 'company'),\n",
       " ('company', 'sale'),\n",
       " ('sale', 'also'),\n",
       " ('also', 'exceeded'),\n",
       " ('exceeded', 'analyst'),\n",
       " ('analyst', 'estimate'),\n",
       " ('estimate', 'herman'),\n",
       " ('herman', 'miller'),\n",
       " ('miller', 'share'),\n",
       " ('share', 'jumped'),\n",
       " ('jumped', 'afterhours'),\n",
       " ('afterhours', 'trading'),\n",
       " ('trading', 'session'),\n",
       " ('session', 'analysts'),\n",
       " ('analysts', 'expect'),\n",
       " ('expect', 'cantel'),\n",
       " ('cantel', 'medical'),\n",
       " ('medical', 'corp'),\n",
       " ('corp', 'nysecmd'),\n",
       " ('nysecmd', 'report'),\n",
       " ('report', 'quarterly'),\n",
       " ('quarterly', 'loss'),\n",
       " ('loss', 'per'),\n",
       " ('per', 'share'),\n",
       " ('share', 'revenue'),\n",
       " ('revenue', 'million'),\n",
       " ('million', 'opening'),\n",
       " ('opening', 'bell'),\n",
       " ('bell', 'cantel'),\n",
       " ('cantel', 'medical'),\n",
       " ('medical', 'share'),\n",
       " ('share', 'gained'),\n",
       " ('gained', 'afterhours'),\n",
       " ('afterhours', 'trading'),\n",
       " ('trading', 'find'),\n",
       " ('find', 'whats'),\n",
       " ('whats', 'going'),\n",
       " ('going', 'today'),\n",
       " ('today', 'market'),\n",
       " ('market', 'bring'),\n",
       " ('bring', 'question'),\n",
       " ('question', 'benzingas'),\n",
       " ('benzingas', 'premarket'),\n",
       " ('premarket', 'prep'),\n",
       " ('prep', 'choosing'),\n",
       " ('choosing', 'best'),\n",
       " ('best', 'broker'),\n",
       " ('broker', 'important'),\n",
       " ('important', 'part'),\n",
       " ('part', 'successful'),\n",
       " ('successful', 'trader'),\n",
       " ('trader', 'investor'),\n",
       " ('investor', 'moderna'),\n",
       " ('moderna', 'inc'),\n",
       " ('inc', 'nasdaqmrna'),\n",
       " ('nasdaqmrna', 'reported'),\n",
       " ('reported', 'collaboration'),\n",
       " ('collaboration', 'chiesi'),\n",
       " ('chiesi', 'group'),\n",
       " ('group', 'discover'),\n",
       " ('discover', 'develop'),\n",
       " ('develop', 'mrna'),\n",
       " ('mrna', 'pulmonary'),\n",
       " ('pulmonary', 'arterial'),\n",
       " ('arterial', 'hypertension'),\n",
       " ('hypertension', 'company'),\n",
       " ('company', 'also'),\n",
       " ('also', 'announced'),\n",
       " ('announced', 'collaboration'),\n",
       " ('collaboration', 'vertex'),\n",
       " ('vertex', 'treat'),\n",
       " ('treat', 'cystic'),\n",
       " ('cystic', 'fibrosis'),\n",
       " ('fibrosis', 'using'),\n",
       " ('using', 'gene'),\n",
       " ('gene', 'editing'),\n",
       " ('editing', 'moderna'),\n",
       " ('moderna', 'share'),\n",
       " ('share', 'gained'),\n",
       " ('gained', 'afterhours'),\n",
       " ('afterhours', 'trading'),\n",
       " ('trading', 'session'),\n",
       " ('session', 'chewy'),\n",
       " ('chewy', 'inc'),\n",
       " ('inc', 'nysechwy'),\n",
       " ('nysechwy', 'reported'),\n",
       " ('reported', 'public'),\n",
       " ('public', 'offering'),\n",
       " ('offering', 'million'),\n",
       " ('million', 'share'),\n",
       " ('share', 'class'),\n",
       " ('class', 'common'),\n",
       " ('common', 'stock'),\n",
       " ('stock', 'chewy'),\n",
       " ('chewy', 'share'),\n",
       " ('share', 'fell'),\n",
       " ('fell', 'afterhours'),\n",
       " ('afterhours', 'tradingstocks'),\n",
       " ('tradingstocks', 'watch'),\n",
       " ('watch', 'september'),\n",
       " ('september', 'biontech'),\n",
       " ('biontech', 'se'),\n",
       " ('se', 'nasdaqbntx'),\n",
       " ('nasdaqbntx', 'today'),\n",
       " ('today', 'announced'),\n",
       " ('announced', 'signing'),\n",
       " ('signing', 'share'),\n",
       " ('share', 'purchase'),\n",
       " ('purchase', 'agreement'),\n",
       " ('agreement', 'novartis'),\n",
       " ('novartis', 'ag'),\n",
       " ('ag', 'basel'),\n",
       " ('basel', 'switzerland'),\n",
       " ('switzerland', 'nysenvs'),\n",
       " ('nysenvs', 'acquire'),\n",
       " ('acquire', 'gmp'),\n",
       " ('gmp', 'certified'),\n",
       " ('certified', 'manufacturing'),\n",
       " ('manufacturing', 'facility'),\n",
       " ('facility', 'marburg'),\n",
       " ('marburg', 'germany'),\n",
       " ('germany', 'manufacturing'),\n",
       " ('manufacturing', 'site'),\n",
       " ('site', 'expand'),\n",
       " ('expand', 'biontechs'),\n",
       " ('biontechs', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'production'),\n",
       " ('production', 'capacity'),\n",
       " ('capacity', 'million'),\n",
       " ('million', 'dos'),\n",
       " ('dos', 'per'),\n",
       " ('per', 'year'),\n",
       " ('year', 'million'),\n",
       " ('million', 'dos'),\n",
       " ('dos', 'per'),\n",
       " ('per', 'month'),\n",
       " ('month', 'fully'),\n",
       " ('fully', 'operational'),\n",
       " ('operational', 'transaction'),\n",
       " ('transaction', 'expected'),\n",
       " ('expected', 'close'),\n",
       " ('close', 'fourth'),\n",
       " ('fourth', 'quarter'),\n",
       " ('quarter', 'company'),\n",
       " ('company', 'plan'),\n",
       " ('plan', 'able'),\n",
       " ('able', 'produce'),\n",
       " ('produce', 'million'),\n",
       " ('million', 'dos'),\n",
       " ('dos', 'bntb'),\n",
       " ('bntb', 'first'),\n",
       " ('first', 'half'),\n",
       " ('half', 'thanks'),\n",
       " ('thanks', 'established'),\n",
       " ('established', 'team'),\n",
       " ('team', 'wellestablished'),\n",
       " ('wellestablished', 'drug'),\n",
       " ('drug', 'substance'),\n",
       " ('substance', 'drug'),\n",
       " ('drug', 'product'),\n",
       " ('product', 'manufacturing'),\n",
       " ('manufacturing', 'capability'),\n",
       " ('capability', 'site'),\n",
       " ('site', 'marburg'),\n",
       " ('marburg', 'production'),\n",
       " ('production', 'site'),\n",
       " ('site', 'stateoftheart'),\n",
       " ('stateoftheart', 'multiplatform'),\n",
       " ('multiplatform', 'gmp'),\n",
       " ('gmp', 'certified'),\n",
       " ('certified', 'manufacturing'),\n",
       " ('manufacturing', 'facility'),\n",
       " ('facility', 'currently'),\n",
       " ('currently', 'employ'),\n",
       " ('employ', 'approximately'),\n",
       " ('approximately', 'people'),\n",
       " ('people', 'fully'),\n",
       " ('fully', 'equipped'),\n",
       " ('equipped', 'production'),\n",
       " ('production', 'recombinant'),\n",
       " ('recombinant', 'protein'),\n",
       " ('protein', 'well'),\n",
       " ('well', 'cell'),\n",
       " ('cell', 'gene'),\n",
       " ('gene', 'therapy'),\n",
       " ('therapy', 'hold'),\n",
       " ('hold', 'cell'),\n",
       " ('cell', 'culture'),\n",
       " ('culture', 'lab'),\n",
       " ('lab', 'viral'),\n",
       " ('viral', 'vector'),\n",
       " ('vector', 'production'),\n",
       " ('production', 'capability'),\n",
       " ('capability', 'potential'),\n",
       " ('potential', 'longterm'),\n",
       " ('longterm', 'growth'),\n",
       " ('growth', 'expansion'),\n",
       " ('expansion', 'novartis'),\n",
       " ('novartis', 'ha'),\n",
       " ('ha', 'significantly'),\n",
       " ('significantly', 'invested'),\n",
       " ('invested', 'site'),\n",
       " ('site', 'past'),\n",
       " ('past', 'five'),\n",
       " ('five', 'year'),\n",
       " ('year', 'located'),\n",
       " ('located', 'life'),\n",
       " ('life', 'science'),\n",
       " ('science', 'industry'),\n",
       " ('industry', 'park'),\n",
       " ('park', 'home'),\n",
       " ('home', 'company'),\n",
       " ('company', 'employee'),\n",
       " ('employee', 'total'),\n",
       " ('total', 'also'),\n",
       " ('also', 'provides'),\n",
       " ('provides', 'excellent'),\n",
       " ('excellent', 'infrastructure'),\n",
       " ('infrastructure', 'company'),\n",
       " ('company', 'industrial'),\n",
       " ('industrial', 'park'),\n",
       " ('park', 'located'),\n",
       " ('located', 'within'),\n",
       " ('within', 'one'),\n",
       " ('one', 'hour'),\n",
       " ('hour', 'frankfurt'),\n",
       " ('frankfurt', 'airport'),\n",
       " ('airport', 'within'),\n",
       " ('within', 'minute'),\n",
       " ('minute', 'biontechs'),\n",
       " ('biontechs', 'headquarters'),\n",
       " ('headquarters', 'mainz'),\n",
       " ('mainz', 'germany'),\n",
       " ('germany', 'acquisition'),\n",
       " ('acquisition', 'reflects'),\n",
       " ('reflects', 'biontechs'),\n",
       " ('biontechs', 'commitment'),\n",
       " ('commitment', 'significantly'),\n",
       " ('significantly', 'expanding'),\n",
       " ('expanding', 'manufacturing'),\n",
       " ('manufacturing', 'capacity'),\n",
       " ('capacity', 'order'),\n",
       " ('order', 'supply'),\n",
       " ('supply', 'potential'),\n",
       " ('potential', 'vaccine'),\n",
       " ('vaccine', 'worldwide'),\n",
       " ('worldwide', 'upon'),\n",
       " ('upon', 'authorization'),\n",
       " ('authorization', 'approval'),\n",
       " ('approval', 'working'),\n",
       " ('working', 'closely'),\n",
       " ('closely', 'novartis'),\n",
       " ('novartis', 'prepare'),\n",
       " ('prepare', 'smooth'),\n",
       " ('smooth', 'transition'),\n",
       " ('transition', 'look'),\n",
       " ('look', 'forward'),\n",
       " ('forward', 'welcoming'),\n",
       " ('welcoming', 'new'),\n",
       " ('new', 'member'),\n",
       " ('member', 'team'),\n",
       " ('team', 'tapping'),\n",
       " ('tapping', 'impressive'),\n",
       " ('impressive', 'skill'),\n",
       " ('skill', 'expertise'),\n",
       " ('expertise', 'strategic'),\n",
       " ('strategic', 'standpoint'),\n",
       " ('standpoint', 'new'),\n",
       " ('new', 'site'),\n",
       " ('site', 'bolster'),\n",
       " ('bolster', 'vertically'),\n",
       " ('vertically', 'integrated'),\n",
       " ('integrated', 'business'),\n",
       " ('business', 'model'),\n",
       " ('model', 'inhouse'),\n",
       " ('inhouse', 'manufacturing'),\n",
       " ('manufacturing', 'capability'),\n",
       " ('capability', 'mrna'),\n",
       " ('mrna', 'manufacturing'),\n",
       " ('manufacturing', 'well'),\n",
       " ('well', 'vaccine'),\n",
       " ('vaccine', 'formulation'),\n",
       " ('formulation', 'said'),\n",
       " ('said', 'dr'),\n",
       " ('dr', 'sierk'),\n",
       " ('sierk', 'poetting'),\n",
       " ('poetting', 'chief'),\n",
       " ('chief', 'financial'),\n",
       " ('financial', 'officer'),\n",
       " ('officer', 'chief'),\n",
       " ('chief', 'operating'),\n",
       " ('operating', 'officer'),\n",
       " ('officer', 'biontech'),\n",
       " ('biontech', 'acquisition'),\n",
       " ('acquisition', 'accelerate'),\n",
       " ('accelerate', 'biontechs'),\n",
       " ('biontechs', 'effort'),\n",
       " ('effort', 'scaleup'),\n",
       " ('scaleup', 'commercial'),\n",
       " ('commercial', 'manufacturing'),\n",
       " ('manufacturing', 'capacity'),\n",
       " ('capacity', 'produce'),\n",
       " ('produce', 'mrna'),\n",
       " ('mrna', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'candidate'),\n",
       " ('candidate', 'bnt'),\n",
       " ('bnt', 'bnt'),\n",
       " ('bnt', 'program'),\n",
       " ('program', 'includes'),\n",
       " ('includes', 'five'),\n",
       " ('five', 'mrna'),\n",
       " ('mrna', 'vaccine'),\n",
       " ('vaccine', 'candidate'),\n",
       " ('candidate', 'currently'),\n",
       " ('currently', 'clinical'),\n",
       " ('clinical', 'testing'),\n",
       " ('testing', 'united'),\n",
       " ('united', 'states'),\n",
       " ('states', 'europe'),\n",
       " ('europe', 'south'),\n",
       " ('south', 'america'),\n",
       " ('america', 'china'),\n",
       " ('china', 'biontech'),\n",
       " ('biontech', 'pfizer'),\n",
       " ('pfizer', 'evaluating'),\n",
       " ('evaluating', 'lead'),\n",
       " ('lead', 'candidate'),\n",
       " ('candidate', 'bntb'),\n",
       " ('bntb', 'global'),\n",
       " ('global', 'phase'),\n",
       " ('phase', 'trial'),\n",
       " ('trial', 'facility'),\n",
       " ('facility', 'expected'),\n",
       " ('expected', 'operate'),\n",
       " ('operate', 'one'),\n",
       " ('one', 'largest'),\n",
       " ('largest', 'mrna'),\n",
       " ('mrna', 'manufacturing'),\n",
       " ('manufacturing', 'site'),\n",
       " ('site', 'europe'),\n",
       " ('europe', 'alongside'),\n",
       " ('alongside', 'two'),\n",
       " ('two', 'biontechs'),\n",
       " ('biontechs', 'existing'),\n",
       " ('existing', 'gmp'),\n",
       " ('gmp', 'facility'),\n",
       " ('facility', 'currently'),\n",
       " ('currently', 'produce'),\n",
       " ('produce', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'candidate'),\n",
       " ('candidate', 'clinical'),\n",
       " ('clinical', 'trial'),\n",
       " ('trial', 'addition'),\n",
       " ('addition', 'least'),\n",
       " ('least', 'four'),\n",
       " ('four', 'pfizer'),\n",
       " ('pfizer', 'production'),\n",
       " ('production', 'site'),\n",
       " ('site', 'united'),\n",
       " ('united', 'states'),\n",
       " ('states', 'europe'),\n",
       " ('europe', 'marburg'),\n",
       " ('marburg', 'facility'),\n",
       " ('facility', 'expected'),\n",
       " ('expected', 'start'),\n",
       " ('start', 'production'),\n",
       " ('production', 'mrna'),\n",
       " ('mrna', 'lnp'),\n",
       " ('lnp', 'formulation'),\n",
       " ('formulation', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'first'),\n",
       " ('first', 'half'),\n",
       " ('half', 'pending'),\n",
       " ('pending', 'regulatory'),\n",
       " ('regulatory', 'authorization'),\n",
       " ('authorization', 'approval'),\n",
       " ('approval', 'biontech'),\n",
       " ('biontech', 'plan'),\n",
       " ('plan', 'manufacture'),\n",
       " ('manufacture', 'additional'),\n",
       " ('additional', 'therapeutic'),\n",
       " ('therapeutic', 'vaccine'),\n",
       " ('vaccine', 'drug'),\n",
       " ('drug', 'candidate'),\n",
       " ('candidate', 'plant'),\n",
       " ('plant', 'mrna'),\n",
       " ('mrna', 'vaccine'),\n",
       " ('vaccine', 'antibody'),\n",
       " ('antibody', 'cell'),\n",
       " ('cell', 'gene'),\n",
       " ('gene', 'therapy'),\n",
       " ('therapy', 'product'),\n",
       " ('product', 'candidate'),\n",
       " ('candidate', 'support'),\n",
       " ('support', 'development'),\n",
       " ('development', 'diversified'),\n",
       " ('diversified', 'cancer'),\n",
       " ('cancer', 'infectious'),\n",
       " ('infectious', 'disease'),\n",
       " ('disease', 'product'),\n",
       " ('product', 'pipeline'),\n",
       " ('pipeline', 'addition'),\n",
       " ('addition', 'biontech'),\n",
       " ('biontech', 'intends'),\n",
       " ('intends', 'use'),\n",
       " ('use', 'marburg'),\n",
       " ('marburg', 'facility'),\n",
       " ('facility', 'contribute'),\n",
       " ('contribute', 'production'),\n",
       " ('production', 'covid'),\n",
       " ('covid', 'vaccine'),\n",
       " ('vaccine', 'global'),\n",
       " ('global', 'supply'),\n",
       " ('supply', 'including'),\n",
       " ('including', 'china'),\n",
       " ('china', 'partnered'),\n",
       " ('partnered', 'fosun'),\n",
       " ('fosun', 'pharma'),\n",
       " ('pharma', 'subject'),\n",
       " ('subject', 'regulatory'),\n",
       " ('regulatory', 'authorization'),\n",
       " ('authorization', 'approval'),\n",
       " ('approval', 'marburg'),\n",
       " ('marburg', 'facility'),\n",
       " ('facility', 'ha'),\n",
       " ('ha', 'year'),\n",
       " ('year', 'long'),\n",
       " ('long', 'tradition'),\n",
       " ('tradition', 'innovation'),\n",
       " ('innovation', 'manufacturing'),\n",
       " ('manufacturing', 'site'),\n",
       " ('site', 'named'),\n",
       " ('named', 'behringwerke'),\n",
       " ('behringwerke', 'wa'),\n",
       " ('wa', 'established'),\n",
       " ('established', 'emil'),\n",
       " ('emil', 'von'),\n",
       " ('von', 'behring'),\n",
       " ('behring', 'developed'),\n",
       " ('developed', 'antitoxin'),\n",
       " ('antitoxin', 'diphtheria'),\n",
       " ('diphtheria', 'tetanus'),\n",
       " ('tetanus', 'used'),\n",
       " ('used', 'award'),\n",
       " ('award', 'money'),\n",
       " ('money', 'received'),\n",
       " ('received', 'nobel'),\n",
       " ('nobel', 'prize'),\n",
       " ('prize', 'medicine'),\n",
       " ('medicine', 'finance'),\n",
       " ('finance', 'manufacturing'),\n",
       " ('manufacturing', 'site'),\n",
       " ('site', 'since'),\n",
       " ('since', 'founding'),\n",
       " ('founding', 'behringwerke'),\n",
       " ('behringwerke', 'ha'),\n",
       " ('ha', 'forefront'),\n",
       " ('forefront', 'pharmaceutical'),\n",
       " ('pharmaceutical', 'biologic'),\n",
       " ('biologic', 'innovation'),\n",
       " ('innovation', 'including'),\n",
       " ('including', 'production'),\n",
       " ('production', 'vaccine'),\n",
       " ('vaccine', 'resulting'),\n",
       " ('resulting', 'highly'),\n",
       " ('highly', 'established'),\n",
       " ('established', 'infrastructure'),\n",
       " ('infrastructure', 'biontech'),\n",
       " ('biontech', 'novartis'),\n",
       " ('novartis', 'anticipate'),\n",
       " ('anticipate', 'completing'),\n",
       " ('completing', 'transaction'),\n",
       " ('transaction', 'fourth'),\n",
       " ('fourth', 'quarter'),\n",
       " ('quarter', 'subject'),\n",
       " ('subject', 'regulatory'),\n",
       " ('regulatory', 'approval'),\n",
       " ('approval', 'satisfaction'),\n",
       " ('satisfaction', 'certain'),\n",
       " ('certain', 'customary'),\n",
       " ('customary', 'closing'),\n",
       " ('closing', 'conditionbiontech'),\n",
       " ('conditionbiontech', 'buys'),\n",
       " ('buys', 'german'),\n",
       " ('german', 'biotech'),\n",
       " ('biotech', 'production'),\n",
       " ('production', 'site'),\n",
       " ('site', 'novartis'),\n",
       " ('novartis', 'increase'),\n",
       " ('increase', 'vaccine'),\n",
       " ('vaccine', 'output'),\n",
       " ('output', 'astrazeneca'),\n",
       " ('astrazeneca', 'nyseazn'),\n",
       " ('nyseazn', 'ha'),\n",
       " ('ha', 'entered'),\n",
       " ('entered', 'agreement'),\n",
       " ('agreement', 'dogma'),\n",
       " ('dogma', 'therapeutics'),\n",
       " ('therapeutics', 'acquire'),\n",
       " ('acquire', 'preclinical'),\n",
       " ('preclinical', 'oral'),\n",
       " ('oral', 'pcsk'),\n",
       " ('pcsk', 'inhibitor'),\n",
       " ('inhibitor', 'programme'),\n",
       " ('programme', 'company'),\n",
       " ('company', 'aim'),\n",
       " ('aim', 'take'),\n",
       " ('take', 'programme'),\n",
       " ('programme', 'forward'),\n",
       " ('forward', 'clinical'),\n",
       " ('clinical', 'development'),\n",
       " ('development', 'dyslipidaemia'),\n",
       " ('dyslipidaemia', 'abnormal'),\n",
       " ('abnormal', 'amount'),\n",
       " ('amount', 'lipid'),\n",
       " ('lipid', 'blood'),\n",
       " ('blood', 'familial'),\n",
       " ('familial', 'hypercholesterolemia'),\n",
       " ('hypercholesterolemia', 'common'),\n",
       " ('common', 'genetic'),\n",
       " ('genetic', 'condition'),\n",
       " ('condition', 'cause'),\n",
       " ('cause', 'high'),\n",
       " ('high', 'cholesterol'),\n",
       " ('cholesterol', 'pcsk'),\n",
       " ('pcsk', 'protein'),\n",
       " ('protein', 'regulates'),\n",
       " ('regulates', 'level'),\n",
       " ('level', 'lowdensity'),\n",
       " ('lowdensity', 'lipoprotein'),\n",
       " ('lipoprotein', 'ldl'),\n",
       " ('ldl', 'bad'),\n",
       " ('bad', 'cholesterol'),\n",
       " ('cholesterol', 'blood'),\n",
       " ('blood', 'increased'),\n",
       " ('increased', 'activity'),\n",
       " ('activity', 'pcsk'),\n",
       " ('pcsk', 'associated'),\n",
       " ('associated', 'high'),\n",
       " ('high', 'ldl'),\n",
       " ('ldl', 'cholesterol'),\n",
       " ('cholesterol', 'acquired'),\n",
       " ('acquired', 'pcsk'),\n",
       " ('pcsk', 'inhibitor'),\n",
       " ('inhibitor', 'small'),\n",
       " ('small', 'molecule'),\n",
       " ('molecule', 'bind'),\n",
       " ('bind', 'directly'),\n",
       " ('directly', 'novel'),\n",
       " ('novel', 'part'),\n",
       " ('part', 'pcsk'),\n",
       " ('pcsk', 'shown'),\n",
       " ('shown', 'block'),\n",
       " ('block', 'activity'),\n",
       " ('activity', 'lower'),\n",
       " ('lower', 'ldl'),\n",
       " ('ldl', 'cholesterol'),\n",
       " ('cholesterol', 'preclinical'),\n",
       " ('preclinical', 'model'),\n",
       " ('model', 'currently'),\n",
       " ('currently', 'oral'),\n",
       " ('oral', 'pcsk'),\n",
       " ('pcsk', 'inhibitor'),\n",
       " ('inhibitor', 'available'),\n",
       " ('available', 'patient'),\n",
       " ('patient', 'clinical'),\n",
       " ('clinical', 'development'),\n",
       " ('development', 'mene'),\n",
       " ('mene', 'pangalos'),\n",
       " ('pangalos', 'executive'),\n",
       " ('executive', 'vice'),\n",
       " ('vice', 'president'),\n",
       " ('president', 'biopharmaceuticals'),\n",
       " ('biopharmaceuticals', 'rd'),\n",
       " ('rd', 'said'),\n",
       " ('said', 'raised'),\n",
       " ('raised', 'ldl'),\n",
       " ('ldl', 'cholesterol'),\n",
       " ('cholesterol', 'key'),\n",
       " ('key', 'risk'),\n",
       " ('risk', 'factor'),\n",
       " ('factor', 'cardiovascular'),\n",
       " ('cardiovascular', 'disease'),\n",
       " ('disease', 'estimated'),\n",
       " ('estimated', 'cause'),\n",
       " ('cause', 'million'),\n",
       " ('million', 'death'),\n",
       " ('death', 'worldwide'),\n",
       " ('worldwide', 'every'),\n",
       " ('every', 'year'),\n",
       " ('year', 'whilst'),\n",
       " ('whilst', 'pcsk'),\n",
       " ('pcsk', 'well'),\n",
       " ('well', 'validated'),\n",
       " ('validated', 'target'),\n",
       " ('target', 'lowering'),\n",
       " ('lowering', 'ldl'),\n",
       " ('ldl', 'cholesterol'),\n",
       " ('cholesterol', 'ha'),\n",
       " ('ha', 'hugely'),\n",
       " ('hugely', 'challenging'),\n",
       " ('challenging', 'target'),\n",
       " ('target', 'inhibit'),\n",
       " ('inhibit', 'small'),\n",
       " ('small', 'molecule'),\n",
       " ('molecule', 'agreement'),\n",
       " ('agreement', 'dogma'),\n",
       " ('dogma', 'therapeutics'),\n",
       " ('therapeutics', 'offer'),\n",
       " ('offer', 'u'),\n",
       " ('u', 'opportunity'),\n",
       " ('opportunity', 'develop'),\n",
       " ('develop', 'first'),\n",
       " ('first', 'small'),\n",
       " ('small', 'molecule'),\n",
       " ('molecule', 'orally'),\n",
       " ('orally', 'bioavailable'),\n",
       " ('bioavailable', 'pcsk'),\n",
       " ('pcsk', 'inhibitor'),\n",
       " ('inhibitor', 'patient'),\n",
       " ('patient', 'risk'),\n",
       " ('risk', 'cardiovascular'),\n",
       " ('cardiovascular', 'disease'),\n",
       " ('disease', 'brian'),\n",
       " ('brian', 'hubbard'),\n",
       " ('hubbard', 'chief'),\n",
       " ('chief', 'executive'),\n",
       " ('executive', 'officer'),\n",
       " ('officer', 'dogma'),\n",
       " ('dogma', 'therapeutics'),\n",
       " ('therapeutics', 'said'),\n",
       " ('said', 'built'),\n",
       " ...]"
      ]
     },
     "metadata": {},
     "execution_count": 113
    }
   ],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "source": [
    "news_word_count = Counter([word for value in news_df['word_tokens'].values for word in value.split()])\r\n",
    "news_word_count"
   ],
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "Counter({'astrazeneca': 1358,\n",
       "         'plcs': 74,\n",
       "         'nyseazn': 163,\n",
       "         'vaccine': 8754,\n",
       "         'didnt': 80,\n",
       "         'likely': 1229,\n",
       "         'cause': 286,\n",
       "         'adverse': 464,\n",
       "         'event': 628,\n",
       "         'suspended': 49,\n",
       "         'latestage': 252,\n",
       "         'human': 303,\n",
       "         'trial': 2732,\n",
       "         'drug': 1706,\n",
       "         'according': 702,\n",
       "         'oxford': 211,\n",
       "         'university': 201,\n",
       "         'happened': 237,\n",
       "         'volunteers': 20,\n",
       "         'british': 69,\n",
       "         'drugmakers': 60,\n",
       "         'chadox': 19,\n",
       "         'ncov': 19,\n",
       "         'developed': 342,\n",
       "         'unexplained': 33,\n",
       "         'neurological': 57,\n",
       "         'symptom': 201,\n",
       "         'including': 965,\n",
       "         'changed': 140,\n",
       "         'sensation': 20,\n",
       "         'weakness': 88,\n",
       "         'limb': 36,\n",
       "         'participant': 782,\n",
       "         'information': 551,\n",
       "         'document': 93,\n",
       "         'published': 181,\n",
       "         'codeveloping': 24,\n",
       "         'independent': 162,\n",
       "         'review': 636,\n",
       "         'illness': 101,\n",
       "         'either': 206,\n",
       "         'considered': 161,\n",
       "         'unlikely': 51,\n",
       "         'associated': 209,\n",
       "         'wa': 4472,\n",
       "         'insufficient': 36,\n",
       "         'evidence': 138,\n",
       "         'say': 240,\n",
       "         'certain': 193,\n",
       "         'related': 828,\n",
       "         'said': 3667,\n",
       "         'first': 1604,\n",
       "         'reported': 1692,\n",
       "         'reuters': 353,\n",
       "         'reviewer': 19,\n",
       "         'recommended': 140,\n",
       "         'vaccination': 545,\n",
       "         'continue': 462,\n",
       "         'reviewing': 48,\n",
       "         'case': 950,\n",
       "         'matters': 128,\n",
       "         'ha': 4012,\n",
       "         'resumed': 61,\n",
       "         'united': 469,\n",
       "         'kingdom': 98,\n",
       "         'india': 335,\n",
       "         'south': 307,\n",
       "         'africa': 149,\n",
       "         'brazil': 177,\n",
       "         'trials': 79,\n",
       "         'havent': 28,\n",
       "         'yet': 285,\n",
       "         'states': 303,\n",
       "         'food': 357,\n",
       "         'administration': 591,\n",
       "         'commissioner': 36,\n",
       "         'stephen': 37,\n",
       "         'hahn': 19,\n",
       "         'agency': 469,\n",
       "         'going': 359,\n",
       "         'significant': 423,\n",
       "         'work': 287,\n",
       "         'company': 6159,\n",
       "         'figure': 41,\n",
       "         'safety': 1213,\n",
       "         'issue': 201,\n",
       "         'moderna': 3112,\n",
       "         'inc': 11376,\n",
       "         'nysemrna': 22,\n",
       "         'pfizer': 2185,\n",
       "         'nysepfe': 607,\n",
       "         'frontrunners': 27,\n",
       "         'race': 86,\n",
       "         'covid': 5292,\n",
       "         'microsoft': 90,\n",
       "         'corporation': 815,\n",
       "         'nasdaqmsft': 60,\n",
       "         'cofounder': 55,\n",
       "         'bill': 122,\n",
       "         'gates': 63,\n",
       "         'claimed': 43,\n",
       "         'pfizers': 284,\n",
       "         'may': 1334,\n",
       "         'get': 366,\n",
       "         'emergency': 749,\n",
       "         'use': 1385,\n",
       "         'license': 269,\n",
       "         'end': 1033,\n",
       "         'october': 255,\n",
       "         'cnbc': 152,\n",
       "         'price': 3750,\n",
       "         'action': 383,\n",
       "         'share': 12488,\n",
       "         'closed': 788,\n",
       "         'almost': 127,\n",
       "         'lower': 721,\n",
       "         'wednesday': 1595,\n",
       "         'gained': 639,\n",
       "         'afterhours': 730,\n",
       "         'sessionastrazeneca': 21,\n",
       "         'events': 93,\n",
       "         'unrelated': 20,\n",
       "         'sinovac': 57,\n",
       "         'biotech': 1403,\n",
       "         'plan': 683,\n",
       "         'expand': 222,\n",
       "         'clinical': 1869,\n",
       "         'child': 240,\n",
       "         'adolescent': 189,\n",
       "         'later': 188,\n",
       "         'month': 1251,\n",
       "         'chinese': 139,\n",
       "         'maker': 151,\n",
       "         'hope': 106,\n",
       "         'carry': 38,\n",
       "         'study': 3328,\n",
       "         'healthy': 136,\n",
       "         'ranging': 31,\n",
       "         'age': 534,\n",
       "         'three': 562,\n",
       "         'filed': 193,\n",
       "         'national': 294,\n",
       "         'library': 19,\n",
       "         'medicine': 639,\n",
       "         'combined': 198,\n",
       "         'phase': 3199,\n",
       "         'take': 318,\n",
       "         'place': 138,\n",
       "         'chinas': 181,\n",
       "         'hebei': 16,\n",
       "         'province': 23,\n",
       "         'commence': 63,\n",
       "         'sept': 196,\n",
       "         'asfirst': 16,\n",
       "         'noticed': 25,\n",
       "         'drugmaker': 75,\n",
       "         'volunteer': 117,\n",
       "         'would': 586,\n",
       "         'given': 416,\n",
       "         'two': 890,\n",
       "         'dos': 1394,\n",
       "         'coronavac': 20,\n",
       "         'vaccineor': 16,\n",
       "         'alternatively': 17,\n",
       "         'placebo': 339,\n",
       "         'already': 233,\n",
       "         'approved': 791,\n",
       "         'regulator': 208,\n",
       "         'spokesperson': 35,\n",
       "         'told': 155,\n",
       "         'entire': 58,\n",
       "         'population': 285,\n",
       "         'important': 479,\n",
       "         'spread': 70,\n",
       "         'adult': 624,\n",
       "         'school': 73,\n",
       "         'kindergarten': 16,\n",
       "         'noted': 127,\n",
       "         'german': 234,\n",
       "         'partner': 393,\n",
       "         'biontech': 837,\n",
       "         'se': 281,\n",
       "         'nasdaqbntx': 279,\n",
       "         'seeking': 97,\n",
       "         'approval': 1054,\n",
       "         'young': 81,\n",
       "         'year': 2043,\n",
       "         'old': 94,\n",
       "         'nasdaqmrna': 625,\n",
       "         'distributed': 60,\n",
       "         'health': 1348,\n",
       "         'care': 418,\n",
       "         'worker': 81,\n",
       "         'highrisk': 94,\n",
       "         'group': 1215,\n",
       "         'late': 225,\n",
       "         'early': 623,\n",
       "         'november': 314,\n",
       "         'new': 7030,\n",
       "         'york': 206,\n",
       "         'times': 145,\n",
       "         'wasntthe': 16,\n",
       "         'halted': 50,\n",
       "         'due': 482,\n",
       "         'earliersinovac': 16,\n",
       "         'plans': 59,\n",
       "         'children': 58,\n",
       "         'adolescents': 48,\n",
       "         'stock': 8258,\n",
       "         'grab': 66,\n",
       "         'investor': 924,\n",
       "         'focus': 495,\n",
       "         'today': 1262,\n",
       "         'wall': 227,\n",
       "         'street': 270,\n",
       "         'expects': 422,\n",
       "         'apogee': 53,\n",
       "         'enterprises': 59,\n",
       "         'nasdaqapog': 37,\n",
       "         'report': 4700,\n",
       "         'quarterly': 3592,\n",
       "         'earnings': 4189,\n",
       "         'per': 4657,\n",
       "         'revenue': 4013,\n",
       "         'million': 5572,\n",
       "         'opening': 123,\n",
       "         'bell': 163,\n",
       "         'slipped': 140,\n",
       "         'trading': 3371,\n",
       "         'herman': 51,\n",
       "         'miller': 56,\n",
       "         'nasdaqmlhr': 34,\n",
       "         'strong': 323,\n",
       "         'rise': 162,\n",
       "         'fiscal': 143,\n",
       "         'quarter': 2182,\n",
       "         'sale': 821,\n",
       "         'also': 1856,\n",
       "         'exceeded': 71,\n",
       "         'analyst': 700,\n",
       "         'estimate': 419,\n",
       "         'jumped': 199,\n",
       "         'session': 2263,\n",
       "         'analysts': 233,\n",
       "         'expect': 199,\n",
       "         'cantel': 50,\n",
       "         'medical': 1012,\n",
       "         'corp': 884,\n",
       "         'nysecmd': 34,\n",
       "         'loss': 1236,\n",
       "         'find': 173,\n",
       "         'whats': 185,\n",
       "         'market': 2580,\n",
       "         'bring': 196,\n",
       "         'question': 169,\n",
       "         'benzingas': 168,\n",
       "         'premarket': 1726,\n",
       "         'prep': 79,\n",
       "         'choosing': 62,\n",
       "         'best': 199,\n",
       "         'broker': 138,\n",
       "         'part': 469,\n",
       "         'successful': 138,\n",
       "         'trader': 387,\n",
       "         'collaboration': 667,\n",
       "         'chiesi': 99,\n",
       "         'discover': 129,\n",
       "         'develop': 346,\n",
       "         'mrna': 2301,\n",
       "         'pulmonary': 149,\n",
       "         'arterial': 100,\n",
       "         'hypertension': 134,\n",
       "         'announced': 2103,\n",
       "         'vertex': 169,\n",
       "         'treat': 316,\n",
       "         'cystic': 113,\n",
       "         'fibrosis': 132,\n",
       "         'using': 404,\n",
       "         'gene': 378,\n",
       "         'editing': 91,\n",
       "         'chewy': 41,\n",
       "         'nysechwy': 20,\n",
       "         'public': 667,\n",
       "         'offering': 721,\n",
       "         'class': 140,\n",
       "         'common': 916,\n",
       "         'fell': 1224,\n",
       "         'tradingstocks': 38,\n",
       "         'watch': 155,\n",
       "         'september': 340,\n",
       "         'signing': 40,\n",
       "         'purchase': 252,\n",
       "         'agreement': 1014,\n",
       "         'novartis': 205,\n",
       "         'ag': 182,\n",
       "         'basel': 36,\n",
       "         'switzerland': 69,\n",
       "         'nysenvs': 67,\n",
       "         'acquire': 153,\n",
       "         'gmp': 71,\n",
       "         'certified': 48,\n",
       "         'manufacturing': 1047,\n",
       "         'facility': 428,\n",
       "         'marburg': 113,\n",
       "         'germany': 117,\n",
       "         'site': 486,\n",
       "         'biontechs': 155,\n",
       "         'production': 593,\n",
       "         'capacity': 264,\n",
       "         'fully': 173,\n",
       "         'operational': 99,\n",
       "         'transaction': 184,\n",
       "         'expected': 1847,\n",
       "         'close': 2084,\n",
       "         'fourth': 385,\n",
       "         'able': 159,\n",
       "         'produce': 194,\n",
       "         'bntb': 183,\n",
       "         'half': 251,\n",
       "         'thanks': 57,\n",
       "         'established': 141,\n",
       "         'team': 180,\n",
       "         'wellestablished': 33,\n",
       "         'substance': 83,\n",
       "         'product': 791,\n",
       "         'capability': 149,\n",
       "         'stateoftheart': 22,\n",
       "         'multiplatform': 17,\n",
       "         'currently': 421,\n",
       "         'employ': 25,\n",
       "         'approximately': 241,\n",
       "         'people': 718,\n",
       "         'equipped': 25,\n",
       "         'recombinant': 44,\n",
       "         'protein': 216,\n",
       "         'well': 694,\n",
       "         'cell': 811,\n",
       "         'therapy': 1048,\n",
       "         'hold': 310,\n",
       "         'culture': 25,\n",
       "         'lab': 100,\n",
       "         'viral': 97,\n",
       "         'vector': 45,\n",
       "         'potential': 870,\n",
       "         'longterm': 224,\n",
       "         'growth': 525,\n",
       "         'expansion': 336,\n",
       "         'significantly': 176,\n",
       "         'invested': 43,\n",
       "         'past': 281,\n",
       "         'five': 264,\n",
       "         'located': 46,\n",
       "         'life': 332,\n",
       "         'science': 197,\n",
       "         'industry': 336,\n",
       "         'park': 50,\n",
       "         'home': 174,\n",
       "         'employee': 90,\n",
       "         'total': 772,\n",
       "         'provides': 163,\n",
       "         'excellent': 33,\n",
       "         'infrastructure': 104,\n",
       "         'industrial': 244,\n",
       "         'within': 361,\n",
       "         'one': 1212,\n",
       "         'hour': 270,\n",
       "         'frankfurt': 22,\n",
       "         'airport': 30,\n",
       "         'minute': 63,\n",
       "         'headquarters': 27,\n",
       "         'mainz': 27,\n",
       "         'acquisition': 355,\n",
       "         'reflects': 46,\n",
       "         'commitment': 137,\n",
       "         'expanding': 66,\n",
       "         'order': 226,\n",
       "         'supply': 923,\n",
       "         'worldwide': 343,\n",
       "         'upon': 122,\n",
       "         'authorization': 759,\n",
       "         'working': 241,\n",
       "         'closely': 58,\n",
       "         'prepare': 40,\n",
       "         'smooth': 24,\n",
       "         'transition': 51,\n",
       "         'look': 375,\n",
       "         'forward': 245,\n",
       "         'welcoming': 19,\n",
       "         'member': 181,\n",
       "         'tapping': 18,\n",
       "         'impressive': 45,\n",
       "         'skill': 23,\n",
       "         'expertise': 68,\n",
       "         'strategic': 201,\n",
       "         'standpoint': 20,\n",
       "         'bolster': 30,\n",
       "         'vertically': 17,\n",
       "         'integrated': 59,\n",
       "         'business': 560,\n",
       "         'model': 108,\n",
       "         'inhouse': 26,\n",
       "         'formulation': 177,\n",
       "         'dr': 244,\n",
       "         'sierk': 18,\n",
       "         'poetting': 19,\n",
       "         'chief': 470,\n",
       "         'financial': 511,\n",
       "         'officer': 393,\n",
       "         'operating': 95,\n",
       "         'accelerate': 153,\n",
       "         'effort': 201,\n",
       "         'scaleup': 24,\n",
       "         'commercial': 465,\n",
       "         'candidate': 1548,\n",
       "         'bnt': 54,\n",
       "         'program': 689,\n",
       "         'includes': 125,\n",
       "         'testing': 225,\n",
       "         'europe': 360,\n",
       "         'america': 187,\n",
       "         'china': 366,\n",
       "         'evaluating': 440,\n",
       "         'lead': 321,\n",
       "         'global': 974,\n",
       "         'operate': 32,\n",
       "         'largest': 162,\n",
       "         'alongside': 46,\n",
       "         'existing': 116,\n",
       "         'addition': 243,\n",
       "         'least': 415,\n",
       "         'four': 257,\n",
       "         'start': 308,\n",
       "         'lnp': 52,\n",
       "         'pending': 90,\n",
       "         'regulatory': 771,\n",
       "         'manufacture': 157,\n",
       "         'additional': 785,\n",
       "         'therapeutic': 548,\n",
       "         'plant': 159,\n",
       "         'antibody': 780,\n",
       "         'support': 463,\n",
       "         'development': 1374,\n",
       "         'diversified': 47,\n",
       "         'cancer': 1860,\n",
       "         'infectious': 190,\n",
       "         'disease': 1806,\n",
       "         'pipeline': 297,\n",
       "         'intends': 156,\n",
       "         'contribute': 34,\n",
       "         'partnered': 46,\n",
       "         'fosun': 33,\n",
       "         'pharma': 617,\n",
       "         'subject': 236,\n",
       "         'long': 149,\n",
       "         'tradition': 16,\n",
       "         'innovation': 132,\n",
       "         'named': 78,\n",
       "         'behringwerke': 32,\n",
       "         'emil': 16,\n",
       "         'von': 25,\n",
       "         'behring': 18,\n",
       "         'antitoxin': 16,\n",
       "         'diphtheria': 16,\n",
       "         'tetanus': 16,\n",
       "         'used': 309,\n",
       "         'award': 40,\n",
       "         'money': 240,\n",
       "         'received': 868,\n",
       "         'nobel': 18,\n",
       "         'prize': 17,\n",
       "         'finance': 66,\n",
       "         'since': 297,\n",
       "         'founding': 22,\n",
       "         'forefront': 26,\n",
       "         'pharmaceutical': 426,\n",
       "         'biologic': 82,\n",
       "         'resulting': 73,\n",
       "         'highly': 204,\n",
       "         'anticipate': 48,\n",
       "         'completing': 31,\n",
       "         'satisfaction': 34,\n",
       "         'customary': 46,\n",
       "         'closing': 343,\n",
       "         'conditionbiontech': 16,\n",
       "         'buys': 26,\n",
       "         'increase': 468,\n",
       "         'output': 45,\n",
       "         'entered': 181,\n",
       "         'dogma': 96,\n",
       "         'therapeutics': 2945,\n",
       "         'preclinical': 196,\n",
       "         'oral': 333,\n",
       "         'pcsk': 197,\n",
       "         'inhibitor': 434,\n",
       "         'programme': 115,\n",
       "         'aim': 143,\n",
       "         'dyslipidaemia': 17,\n",
       "         'abnormal': 30,\n",
       "         'amount': 106,\n",
       "         'lipid': 88,\n",
       "         'blood': 408,\n",
       "         'familial': 28,\n",
       "         'hypercholesterolemia': 22,\n",
       "         'genetic': 148,\n",
       "         'condition': 232,\n",
       "         'high': 7130,\n",
       "         'cholesterol': 133,\n",
       "         'regulates': 16,\n",
       "         'level': 575,\n",
       "         'lowdensity': 19,\n",
       "         'lipoprotein': 23,\n",
       "         'ldl': 100,\n",
       "         'bad': 51,\n",
       "         'increased': 390,\n",
       "         'activity': 1028,\n",
       "         'acquired': 95,\n",
       "         'small': 226,\n",
       "         'molecule': 121,\n",
       "         'bind': 40,\n",
       "         'directly': 68,\n",
       "         'novel': 256,\n",
       "         'shown': 104,\n",
       "         'block': 51,\n",
       "         'available': 590,\n",
       "         'patient': 3049,\n",
       "         'mene': 44,\n",
       "         'pangalos': 47,\n",
       "         'executive': 441,\n",
       "         'vice': 192,\n",
       "         'president': 458,\n",
       "         'biopharmaceuticals': 99,\n",
       "         'rd': 425,\n",
       "         'raised': 189,\n",
       "         'key': 417,\n",
       "         'risk': 779,\n",
       "         'factor': 214,\n",
       "         'cardiovascular': 187,\n",
       "         'estimated': 1229,\n",
       "         'death': 483,\n",
       "         'every': 167,\n",
       "         'whilst': 17,\n",
       "         'validated': 41,\n",
       "         'target': 860,\n",
       "         'lowering': 29,\n",
       "         'hugely': 18,\n",
       "         'challenging': 29,\n",
       "         'inhibit': 24,\n",
       "         'offer': 302,\n",
       "         'u': 240,\n",
       "         'opportunity': 241,\n",
       "         'orally': 57,\n",
       "         'bioavailable': 17,\n",
       "         'brian': 34,\n",
       "         'hubbard': 16,\n",
       "         'built': 56,\n",
       "         'robust': 98,\n",
       "         'data': 2817,\n",
       "         'package': 60,\n",
       "         'highlight': 50,\n",
       "         'cholesterollowering': 17,\n",
       "         'meet': 224,\n",
       "         'goal': 163,\n",
       "         'access': 226,\n",
       "         'unable': 42,\n",
       "         'anticipates': 58,\n",
       "         'entering': 67,\n",
       "         'developmentastrazeneca': 16,\n",
       "         'acquires': 27,\n",
       "         'terms': 26,\n",
       "         'disclosed': 123,\n",
       "         'preopen': 84,\n",
       "         'mover': 99,\n",
       "         'us': 2548,\n",
       "         'future': 964,\n",
       "         'traded': 2594,\n",
       "         'trade': 1070,\n",
       "         'mostly': 127,\n",
       "         'previous': 413,\n",
       "         'federal': 261,\n",
       "         'reserve': 122,\n",
       "         'maintained': 89,\n",
       "         'current': 554,\n",
       "         'fed': 270,\n",
       "         'fund': 295,\n",
       "         'range': 254,\n",
       "         'zero': 30,\n",
       "         'investors': 378,\n",
       "         'awaiting': 84,\n",
       "         'initial': 412,\n",
       "         'jobless': 83,\n",
       "         'claim': 119,\n",
       "         'latest': 202,\n",
       "         'week': 7181,\n",
       "         'released': 266,\n",
       "         'et': 465,\n",
       "         'project': 63,\n",
       "         'declining': 109,\n",
       "         'housing': 45,\n",
       "         'building': 94,\n",
       "         'permit': 25,\n",
       "         'august': 248,\n",
       "         'philadelphia': 30,\n",
       "         'index': 1012,\n",
       "         'futures': 290,\n",
       "         'dow': 224,\n",
       "         'jones': 178,\n",
       "         'average': 377,\n",
       "         'dropped': 277,\n",
       "         'point': 530,\n",
       "         'standard': 314,\n",
       "         'poors': 90,\n",
       "         'nasdaq': 422,\n",
       "         'declined': 221,\n",
       "         'highest': 143,\n",
       "         'number': 550,\n",
       "         'world': 526,\n",
       "         'infection': 496,\n",
       "         'country': 590,\n",
       "         'exceeding': 91,\n",
       "         'around': 538,\n",
       "         'confirmed': 390,\n",
       "         'oil': 283,\n",
       "         'brent': 88,\n",
       "         'crude': 329,\n",
       "         'barrel': 240,\n",
       "         'wti': 95,\n",
       "         'inventory': 82,\n",
       "         'ended': 145,\n",
       "         'energy': 527,\n",
       "         'administrations': 49,\n",
       "         'weekly': 103,\n",
       "         'natural': 99,\n",
       "         'gas': 76,\n",
       "         'underground': 32,\n",
       "         'storage': 142,\n",
       "         'scheduled': 354,\n",
       "         'release': 465,\n",
       "         'peek': 87,\n",
       "         'markets': 264,\n",
       "         'european': 750,\n",
       "         'spanish': 113,\n",
       "         'ibex': 101,\n",
       "         'falling': 56,\n",
       "         'stoxx': 101,\n",
       "         'french': 128,\n",
       "         'cac': 101,\n",
       "         'dax': 100,\n",
       "         'londons': 98,\n",
       "         'ftse': 116,\n",
       "         'car': 84,\n",
       "         'registration': 67,\n",
       "         'union': 189,\n",
       "         'yearoveryear': 194,\n",
       "         'unit': 193,\n",
       "         'asian': 98,\n",
       "         'japans': 126,\n",
       "         'nikkei': 108,\n",
       "         'hong': 130,\n",
       "         'kongs': 103,\n",
       "         'hang': 94,\n",
       "         'seng': 95,\n",
       "         'shanghai': 102,\n",
       "         'composite': 153,\n",
       "         'indias': 123,\n",
       "         'bse': 83,\n",
       "         'sensex': 83,\n",
       "         'bank': 335,\n",
       "         'japan': 237,\n",
       "         'held': 135,\n",
       "         'shortterm': 41,\n",
       "         'interest': 365,\n",
       "         'rate': 592,\n",
       "         'recommendation': 187,\n",
       "         'jp': 79,\n",
       "         'morgan': 206,\n",
       "         'upgraded': 182,\n",
       "         'zoominfo': 41,\n",
       "         'technologies': 546,\n",
       "         'nasdaqzi': 20,\n",
       "         'neutral': 312,\n",
       "         'overweight': 198,\n",
       "         'breaking': 170,\n",
       "         'news': 541,\n",
       "         'planning': 82,\n",
       "         'agreed': 163,\n",
       "         'therapeuticspeek': 16,\n",
       "         'tumble': 17,\n",
       "         'ahead': 530,\n",
       "         'claims': 46,\n",
       "         'maintainedobjective': 16,\n",
       "         'response': 880,\n",
       "         'anddisease': 17,\n",
       "         'control': 299,\n",
       "         'complete': 234,\n",
       "         'xmt': 145,\n",
       "         'continues': 171,\n",
       "         'generally': 291,\n",
       "         'welltolerated': 69,\n",
       "         'signal': 147,\n",
       "         'presented': 223,\n",
       "         'discussed': 53,\n",
       "         'conference': 428,\n",
       "         'call': 1001,\n",
       "         'cambridge': 84,\n",
       "         'mass': 65,\n",
       "         'globe': 56,\n",
       "         'newswire': 71,\n",
       "         'mersana': 168,\n",
       "         'nasdaqmrsn': 55,\n",
       "         'clinicalstage': 131,\n",
       "         'biopharmaceutical': 133,\n",
       "         'focused': 184,\n",
       "         'discovering': 22,\n",
       "         'developing': 331,\n",
       "         'antibodydrug': 31,\n",
       "         'conjugate': 64,\n",
       "         'adcs': 38,\n",
       "         'targeting': 153,\n",
       "         'area': 217,\n",
       "         'unmet': 111,\n",
       "         'need': 482,\n",
       "         'updated': 222,\n",
       "         'interim': 607,\n",
       "         'tolerability': 176,\n",
       "         'efficacy': 840,\n",
       "         'ovarian': 318,\n",
       "         'cohort': 305,\n",
       "         'ongoing': 405,\n",
       "         'portion': 160,\n",
       "         'firstinclass': 64,\n",
       "         'adc': 155,\n",
       "         'napib': 97,\n",
       "         'society': 171,\n",
       "         'oncology': 612,\n",
       "         'esmo': 59,\n",
       "         'virtual': 247,\n",
       "         'congress': 114,\n",
       "         'host': 114,\n",
       "         'webcast': 149,\n",
       "         'etduring': 16,\n",
       "         'investigator': 90,\n",
       "         'erika': 16,\n",
       "         'hamilton': 25,\n",
       "         'md': 131,\n",
       "         'director': 145,\n",
       "         'breast': 271,\n",
       "         'gynecologic': 18,\n",
       "         'research': 630,\n",
       "         'sarah': 24,\n",
       "         'cannon': 20,\n",
       "         'institute': 191,\n",
       "         'tennessee': 24,\n",
       "         'present': 231,\n",
       "         'discus': 184,\n",
       "         'continued': 236,\n",
       "         'dolaflexin': 32,\n",
       "         'recently': 303,\n",
       "         'granted': 242,\n",
       "         'fda': 1696,\n",
       "         'fast': 123,\n",
       "         'track': 185,\n",
       "         'designation': 190,\n",
       "         'eager': 18,\n",
       "         'advance': 196,\n",
       "         'registrationenabling': 25,\n",
       "         'based': 564,\n",
       "         'observed': 334,\n",
       "         'antitumor': 51,\n",
       "         'favorable': 84,\n",
       "         'profile': 262,\n",
       "         'poor': 40,\n",
       "         'prognosis': 31,\n",
       "         'limited': 287,\n",
       "         'treatment': 2023,\n",
       "         'option': 1611,\n",
       "         'anna': 16,\n",
       "         'protopapas': 16,\n",
       "         'additionally': 115,\n",
       "         'presenting': 28,\n",
       "         'comprehensive': 50,\n",
       "         'mature': 28,\n",
       "         'result': 1690,\n",
       "         'analysis': 634,\n",
       "         'heavily': 45,\n",
       "         'pretreated': 28,\n",
       "         'platinumresistant': 38,\n",
       "         'refractory': 110,\n",
       "         'fallopian': 22,\n",
       "         'tube': 22,\n",
       "         'primary': 489,\n",
       "         'peritoneal': 21,\n",
       "         'line': 229,\n",
       "         'prior': 643,\n",
       "         'regardless': 45,\n",
       "         'platinum': 22,\n",
       "         'status': 65,\n",
       "         'cutoff': 40,\n",
       "         'include': 382,\n",
       "         'follow': 100,\n",
       "         'previously': 322,\n",
       "         'american': 349,\n",
       "         'asco': 46,\n",
       "         'finding': 189,\n",
       "         'consistent': 161,\n",
       "         'frequently': 38,\n",
       "         'treatmentrelated': 37,\n",
       "         'traes': 17,\n",
       "         'grade': 111,\n",
       "         'fatigue': 85,\n",
       "         'nausea': 60,\n",
       "         'decreased': 78,\n",
       "         'appetite': 31,\n",
       "         'vomiting': 31,\n",
       "         'transient': 29,\n",
       "         'ast': 17,\n",
       "         'elevation': 28,\n",
       "         'without': 320,\n",
       "         'change': 1995,\n",
       "         'bilirubin': 17,\n",
       "         'hys': 16,\n",
       "         'law': 74,\n",
       "         'severe': 463,\n",
       "         'neutropenia': 56,\n",
       "         'peripheral': 33,\n",
       "         'neuropathy': 21,\n",
       "         'ocular': 52,\n",
       "         'toxicity': 58,\n",
       "         'platinumrefractory': 16,\n",
       "         'treated': 283,\n",
       "         'bevacizumab': 92,\n",
       "         'parp': 66,\n",
       "         'evaluable': 34,\n",
       "         'achieved': 541,\n",
       "         'crs': 37,\n",
       "         'partial': 64,\n",
       "         'prs': 17,\n",
       "         'objective': 92,\n",
       "         'orr': 49,\n",
       "         'stable': 97,\n",
       "         'sd': 17,\n",
       "         'dcr': 20,\n",
       "         'cycle': 68,\n",
       "         'andof': 19,\n",
       "         'responses': 19,\n",
       "         'appeared': 64,\n",
       "         'deepen': 18,\n",
       "         'time': 1030,\n",
       "         'receiving': 184,\n",
       "         'reduced': 152,\n",
       "         'dose': 1143,\n",
       "         'majority': 102,\n",
       "         'responder': 39,\n",
       "         'reduction': 208,\n",
       "         'tumor': 342,\n",
       "         'volume': 408,\n",
       "         'achieving': 45,\n",
       "         'biomarkerbased': 16,\n",
       "         'selection': 57,\n",
       "         'strategy': 315,\n",
       "         'depth': 26,\n",
       "         'quality': 156,\n",
       "         'higher': 1194,\n",
       "         'expression': 81,\n",
       "         'onlyof': 16,\n",
       "         'median': 157,\n",
       "         'duration': 105,\n",
       "         'reached': 488,\n",
       "         'define': 25,\n",
       "         'set': 1679,\n",
       "         'details': 41,\n",
       "         'please': 97,\n",
       "         'dial': 19,\n",
       "         'domestic': 67,\n",
       "         'international': 389,\n",
       "         'provide': 355,\n",
       "         'id': 32,\n",
       "         'live': 137,\n",
       "         'presentation': 202,\n",
       "         'media': 74,\n",
       "         'section': 88,\n",
       "         'website': 128,\n",
       "         'atwwwmersanacom': 16,\n",
       "         'differentiated': 29,\n",
       "         'proprietary': 105,\n",
       "         'platform': 464,\n",
       "         'rapidly': 67,\n",
       "         'optimal': 43,\n",
       "         'meaningfully': 23,\n",
       "         'improve': 134,\n",
       "         'fighting': 32,\n",
       "         'mersanas': 64,\n",
       "         'proofofconcept': 70,\n",
       "         'nsclc': 120,\n",
       "         'adenocarcinoma': 44,\n",
       "         'second': 997,\n",
       "         'napibexpressing': 16,\n",
       "         'created': 78,\n",
       "         'customizable': 16,\n",
       "         'homogeneous': 16,\n",
       "         'dolasynthen': 16,\n",
       "         'escalation': 46,\n",
       "         'companys': 290,\n",
       "         'stage': 242,\n",
       "         'bh': 16,\n",
       "         'stingagonist': 16,\n",
       "         'immunosynthen': 16,\n",
       "         'multiple': 376,\n",
       "         'pipelinemersana': 16,\n",
       "         'announces': 360,\n",
       "         'plc': 673,\n",
       "         'positive': 866,\n",
       "         'cmv': 90,\n",
       "         'begin': 335,\n",
       "         'cove': 148,\n",
       "         'enrolled': 212,\n",
       "         'date': 763,\n",
       "         'protocol': 164,\n",
       "         'online': 131,\n",
       "         'enter': 142,\n",
       "         'seasonal': 190,\n",
       "         'flu': 236,\n",
       "         'effective': 501,\n",
       "         'twodose': 98,\n",
       "         'regimen': 190,\n",
       "         'chikungunya': 119,\n",
       "         'demonstrates': 31,\n",
       "         'ability': 186,\n",
       "         'safe': 199,\n",
       "         'repeat': 60,\n",
       "         'dosing': 198,\n",
       "         'next': 506,\n",
       "         'generation': 122,\n",
       "         'mma': 52,\n",
       "         'biotechnology': 244,\n",
       "         'pioneering': 95,\n",
       "         'messenger': 129,\n",
       "         'rna': 151,\n",
       "         'create': 154,\n",
       "         'transformative': 63,\n",
       "         'progress': 178,\n",
       "         'across': 437,\n",
       "         'portfolio': 259,\n",
       "         'asset': 427,\n",
       "         'annual': 314,\n",
       "         'day': 2485,\n",
       "         'made': 1232,\n",
       "         'last': 1928,\n",
       "         'ago': 138,\n",
       "         'matured': 16,\n",
       "         'actively': 55,\n",
       "         'preparing': 39,\n",
       "         'launch': 152,\n",
       "         'breadth': 24,\n",
       "         'modernas': 686,\n",
       "         'stphane': 98,\n",
       "         'bancel': 129,\n",
       "         'announcing': 35,\n",
       "         'increasing': 83,\n",
       "         'investment': 416,\n",
       "         'systemic': 174,\n",
       "         'secreted': 60,\n",
       "         'surface': 86,\n",
       "         'core': 104,\n",
       "         'modality': 82,\n",
       "         'sharing': 41,\n",
       "         'particularly': 78,\n",
       "         'rare': 309,\n",
       "         'field': 67,\n",
       "         'technology': 690,\n",
       "         'scale': 124,\n",
       "         'commercialization': 183,\n",
       "         'committed': 115,\n",
       "         'ever': 63,\n",
       "         'mission': 69,\n",
       "         'deliver': 260,\n",
       "         'promise': 85,\n",
       "         'prevent': 185,\n",
       "         'serious': 238,\n",
       "         'diseases': 86,\n",
       "         'conducted': 154,\n",
       "         'nih': 83,\n",
       "         'barda': 108,\n",
       "         'transparency': 31,\n",
       "         'context': 58,\n",
       "         'pandemic': 499,\n",
       "         'availableonline': 16,\n",
       "         'g': 193,\n",
       "         'completed': 153,\n",
       "         'investigational': 348,\n",
       "         'ind': 73,\n",
       "         'application': 729,\n",
       "         'pediatric': 255,\n",
       "         'rsv': 156,\n",
       "         'allowed': 74,\n",
       "         'proceed': 48,\n",
       "         'clinic': 118,\n",
       "         'dosed': 166,\n",
       "         'hmpvpiv': 32,\n",
       "         'oxlmrna': 16,\n",
       "         'monotherapy': 125,\n",
       "         ...})"
      ]
     },
     "metadata": {},
     "execution_count": 114
    }
   ],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "source": [
    "import spacy\r\n",
    "from spacy import displacy\r\n",
    "nlp = spacy.load('en_core_web_sm')"
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "source": [
    "news_doc = nlp(big_string[:10000])\r\n",
    "displacy.render(news_doc, style='ent')"
   ],
   "outputs": [
    {
     "output_type": "display_data",
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">astrazeneca plcs nyseazn vaccine didnt likely cause adverse event suspended latestage human trial drug according \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oxford university\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " happened volunteers \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    british\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " drugmakers chadox ncov vaccine trial developed unexplained neurological symptom including changed sensation weakness limb according participant information document published oxford codeveloping vaccine astrazeneca independent review illness either considered unlikely associated vaccine wa insufficient evidence say certain illness related vaccine \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oxford\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " said \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    first\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       " reported \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    reuters\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " independent reviewer recommended vaccination continue reviewing case according document matters astrazeneca ha resumed trial vaccine \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    united kingdom\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    india\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    south africa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " brazil trials havent yet resumed \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    united states food drug administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " commissioner \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    stephen hahn\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " said agency going significant work company figure significant safety issue \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    moderna inc nysemrna pfizer inc nysepfe\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " likely frontrunners race covid vaccine \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    microsoft\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " corporation \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nasdaqmsft\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " cofounder bill gates claimed pfizers vaccine may get emergency use license end \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    october\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " according \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cnbc price\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " action astrazeneca share closed almost lower \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    wednesday\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " gained afterhours sessionastrazeneca trial participant adverse events likely unrelated covid vaccine oxford sinovac biotech ha plan expand clinical trial covid vaccine trial child adolescent \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    later month\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " happened \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chinese\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " vaccine maker hope carry study healthy participant ranging \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    age three\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " according information company filed \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    national library medicine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " combined phase phase trial take place chinas \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hebei\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " province commence sept company said asfirst noticed \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    reuters\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " drugmaker said volunteer would given \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " dos drugmakers coronavac vaccineor alternatively placebo trial ha already approved chinas regulator sinovac spokesperson told reuters matters vaccine work entire population important covid spread adult school kindergarten reuters noted pfizer inc nysepfe \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    german\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " partner biontech se nasdaqbntx seeking approval \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    united states food drug administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " expand drug trial including adolescent young \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    year old\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " pfizer \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    moderna inc nasdaqmrna\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " vaccine likely distributed health care worker highrisk group \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    late october early november\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " according \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    new york times\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oxford university\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " said partner astrazeneca plcs nyseazn covid vaccine wasntthe likely cause neurological symptom weakness limb latestage trial participant \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    british\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " drugmaker ha resumed latestage trial \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    united kingdom\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    india\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " brazil \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    south africa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " halted due reported adverse event earliersinovac plans expand covid vaccine trials children adolescents stock may grab investor focus today wall street expects \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    apogee enterprises inc nasdaqapog\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " report \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    quarterly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " earnings per share revenue \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    million\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " opening \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bell apogee share\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " slipped afterhours trading \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    herman miller inc nasdaqmlhr\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " reported strong rise earnings \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fiscal first quarter\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " company sale also exceeded analyst estimate herman \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    miller\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " share jumped afterhours trading session analysts expect \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cantel medical corp nysecmd report\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    quarterly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " loss per share revenue \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    million\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " opening \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bell cantel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " medical share gained afterhours trading find whats going today market bring question benzingas premarket prep choosing best broker important part successful trader investor \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    moderna inc nasdaqmrna\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " reported collaboration chiesi group discover develop mrna pulmonary arterial hypertension company also announced collaboration vertex treat cystic fibrosis using gene editing moderna share gained afterhours trading session chewy inc nysechwy reported public offering \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    million\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " share class common stock chewy share fell afterhours tradingstocks watch \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    september\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " biontech se nasdaqbntx \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    today\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " announced signing share purchase agreement novartis \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ag\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " basel \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    switzerland\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " nysenvs acquire gmp certified manufacturing facility \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    marburg germany\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " manufacturing site expand biontechs covid vaccine production capacity million dos per year million dos per month fully operational transaction expected close \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fourth quarter\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " company plan able produce \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    million\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " dos bntb \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    first\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    half\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " thanks established team wellestablished drug substance drug product manufacturing capability site marburg production site stateoftheart multiplatform gmp certified manufacturing facility currently employ approximately people fully equipped production recombinant protein well cell gene therapy hold cell culture lab viral vector production capability potential longterm growth expansion novartis ha significantly invested site \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    past five year\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " located life science industry park home company employee total also provides excellent infrastructure company industrial park located within \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    one hour\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">TIME</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    frankfurt\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " airport within minute biontechs headquarters \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mainz germany\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " acquisition reflects biontechs commitment significantly expanding manufacturing capacity order supply potential vaccine worldwide upon authorization approval working closely novartis prepare smooth transition look forward welcoming new member team tapping impressive skill expertise strategic standpoint new site bolster vertically integrated business model inhouse manufacturing capability mrna manufacturing well vaccine formulation said dr sierk poetting chief financial officer chief operating officer biontech acquisition accelerate biontechs effort scaleup commercial manufacturing capacity produce mrna covid vaccine candidate \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bnt bnt\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " program includes \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    five\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " mrna vaccine candidate currently clinical testing united states \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    europe south america\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    china\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " biontech pfizer evaluating lead candidate bntb global phase trial facility expected operate \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    one\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " largest mrna manufacturing site \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    europe\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " alongside \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    two\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " biontechs existing gmp facility currently produce covid vaccine candidate clinical trial addition least \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    four\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " pfizer production site united states \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    europe marburg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " facility expected start production mrna lnp formulation covid vaccine \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    first\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    half\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " pending regulatory authorization approval biontech plan manufacture additional therapeutic vaccine drug candidate plant mrna vaccine antibody cell gene therapy product candidate support development diversified cancer infectious disease product pipeline addition biontech intends use marburg facility contribute production covid vaccine global supply including \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    china\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " partnered fosun pharma subject regulatory authorization approval marburg facility ha year long tradition innovation manufacturing site named behringwerke wa established emil von behring developed antitoxin diphtheria tetanus used award money received nobel prize medicine finance manufacturing site since founding behringwerke ha forefront pharmaceutical biologic innovation including production vaccine resulting highly established infrastructure biontech novartis anticipate completing transaction fourth quarter subject regulatory approval satisfaction certain customary closing conditionbiontech buys \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    german\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " biotech production site novartis increase vaccine output astrazeneca nyseazn ha entered agreement dogma therapeutics acquire preclinical oral pcsk inhibitor programme company aim take programme forward clinical development dyslipidaemia abnormal amount lipid blood familial hypercholesterolemia common genetic condition cause high cholesterol pcsk protein regulates level lowdensity lipoprotein ldl bad cholesterol blood increased activity pcsk associated high ldl cholesterol acquired pcsk inhibitor small molecule bind directly novel part pcsk shown block activity lower ldl cholesterol preclinical model currently oral pcsk inhibitor available patient clinical development mene pangalos executive vice president biopharmaceuticals rd said raised ldl cholesterol key risk factor cardiovascular disease estimated cause \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    million\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " death worldwide \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    every year\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " whilst pcsk well validated target lowering ldl cholesterol ha hugely challenging target inhibit small molecule agreement dogma therapeutics offer u opportunity develop \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    first\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORDINAL</span>\n",
       "</mark>\n",
       " small molecule orally bioavailable pcsk inhibitor patient risk cardiovascular disease brian hubbard chief executive officer dogma therapeutics said built robust data package highlight cholesterollowering safety potential oral pcsk programme agreement astrazeneca meet strategic goal accelerate access patient unable meet target ldl cholesterol astrazeneca anticipates entering clinical developmentastrazeneca acquires oral pcsk inhibitor programme dogma therapeutics financial terms disclosed preopen mover us stock future traded lower early premarket trade closing mostly lower previous session federal reserve maintained current \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " fund target range \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    zero\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " investors awaiting earnings \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    apogee enterprises inc nasdaqapog\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " cantel \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    medical corp nysecmd\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " data initial jobless \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    claim latest week\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " released et analysts project claim declining \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    september week\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " previous week data housing start building permit \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    august\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " philadelphia \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " manufacturing index \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    september\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " released et futures dow jones industrial average dropped point standard poors index future traded fell point futures \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nasdaq\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " index declined point us ha highest number covid case death world total infection country exceeding around death \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    india\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " reported total least confirmed case \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brazil\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " confirmed case oil price traded lower brent crude future fell trade per barrel us wti crude future fell trade barrel us crude inventory dropped million barrel week ended \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    september\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " energy information administration reported energy information administrations \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    weekly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " report natural gas stock underground storage scheduled release et peek global markets \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    european\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " market lower \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    today\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    spanish\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " ibex index falling stoxx \n",
       "<mark class=\"entity\" style=\"background: #ff9561; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    europe\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">LOC</span>\n",
       "</mark>\n",
       " index declining \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    french\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " cac index slipped \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    german\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " dax fell londons ftse fell new car registration \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    european union\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " dropped yearoveryear unit \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    august\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    asian\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " market japans nikkei fell hong kongs \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hang seng\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " index declined chinas \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    shanghai\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " composite index fell indias bse sensex fell bank \n",
       "<mark class=\"entity\" style=\"background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    japan\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">GPE</span>\n",
       "</mark>\n",
       " held key shortterm interest rate broker recommendation analysts jp \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    morgan\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " upgraded \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    zoominfo technologies inc nasdaqzi\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " neutral overweight \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    zoominfo\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CARDINAL</span>\n",
       "</mark>\n",
       " share fell close \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    wednesday\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       " breaking news \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    moderna inc nasdaqmrna\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " reported collaboration chiesi group discover deve</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {}
    }
   ],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "source": [
    "[ent for ent in news_doc.ents]"
   ],
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "[oxford university,\n",
       " british,\n",
       " oxford,\n",
       " first,\n",
       " reuters,\n",
       " united kingdom,\n",
       " india,\n",
       " south africa,\n",
       " united states food drug administration,\n",
       " stephen hahn,\n",
       " moderna inc nysemrna pfizer inc nysepfe,\n",
       " microsoft,\n",
       " nasdaqmsft,\n",
       " october,\n",
       " cnbc price,\n",
       " wednesday,\n",
       " later month,\n",
       " chinese,\n",
       " age three,\n",
       " national library medicine,\n",
       " hebei,\n",
       " reuters,\n",
       " two,\n",
       " german,\n",
       " united states food drug administration,\n",
       " year old,\n",
       " moderna inc nasdaqmrna,\n",
       " late october early november,\n",
       " new york times,\n",
       " oxford university,\n",
       " british,\n",
       " united kingdom,\n",
       " india,\n",
       " south africa,\n",
       " apogee enterprises inc nasdaqapog,\n",
       " quarterly,\n",
       " million,\n",
       " bell apogee share,\n",
       " herman miller inc nasdaqmlhr,\n",
       " fiscal first quarter,\n",
       " miller,\n",
       " cantel medical corp nysecmd report,\n",
       " quarterly,\n",
       " million,\n",
       " bell cantel,\n",
       " moderna inc nasdaqmrna,\n",
       " million,\n",
       " september,\n",
       " today,\n",
       " ag,\n",
       " switzerland,\n",
       " marburg germany,\n",
       " fourth quarter,\n",
       " million,\n",
       " first,\n",
       " half,\n",
       " past five year,\n",
       " one hour,\n",
       " frankfurt,\n",
       " mainz germany,\n",
       " bnt bnt,\n",
       " five,\n",
       " europe south america,\n",
       " china,\n",
       " one,\n",
       " europe,\n",
       " two,\n",
       " four,\n",
       " europe marburg,\n",
       " first,\n",
       " half,\n",
       " china,\n",
       " german,\n",
       " million,\n",
       " every year,\n",
       " first,\n",
       " fed,\n",
       " zero,\n",
       " apogee enterprises inc nasdaqapog,\n",
       " medical corp nysecmd,\n",
       " claim latest week,\n",
       " september week,\n",
       " august,\n",
       " fed,\n",
       " september,\n",
       " nasdaq,\n",
       " india,\n",
       " brazil,\n",
       " september,\n",
       " weekly,\n",
       " european,\n",
       " today,\n",
       " spanish,\n",
       " europe,\n",
       " french,\n",
       " german,\n",
       " european union,\n",
       " august,\n",
       " asian,\n",
       " hang seng,\n",
       " shanghai,\n",
       " japan,\n",
       " morgan,\n",
       " zoominfo technologies inc nasdaqzi,\n",
       " zoominfo,\n",
       " wednesday,\n",
       " moderna inc nasdaqmrna]"
      ]
     },
     "metadata": {},
     "execution_count": 119
    }
   ],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "source": [
    "def clean_html(raw_html):\r\n",
    "    cleanr = re.compile('\\.+|<.*?>|&([a-z0-9]+|#[0-9]{1,6}|#x[0-9a-f]{1,6});')\r\n",
    "    cleantext = re.sub(cleanr, '', raw_html).replace('\\r', ' ').replace('\\t', ' ').replace('\\n', ' ').strip()\r\n",
    "    return ' '.join(cleantext.split())"
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "source": [
    "from nltk.sentiment.vader import SentimentIntensityAnalyzer\r\n",
    "analyzer = SentimentIntensityAnalyzer()\r\n",
    "\r\n",
    "news_features_df = pd.DataFrame()\r\n",
    "news_features_df['date'] = news_df['date']\r\n",
    "news_features_df['symbol'] = news_df['symbol']\r\n",
    "\r\n",
    "news_features_df['compound_b'] = [analyzer.polarity_scores(v)['compound'] for v in news_df['body'].apply(clean_html)]\r\n",
    "news_features_df['neg_b'] = [analyzer.polarity_scores(v)['neg'] for v in news_df['body'].apply(clean_html)]\r\n",
    "news_features_df['neu_b'] = [analyzer.polarity_scores(v)['neu'] for v in news_df['body'].apply(clean_html)]\r\n",
    "news_features_df['pos_b'] = [analyzer.polarity_scores(v)['pos'] for v in news_df['body'].apply(clean_html)]\r\n",
    "\r\n",
    "news_features_df['compound_t'] = [analyzer.polarity_scores(v)['compound'] for v in news_df['title'].apply(clean_html)]\r\n",
    "news_features_df['neg_t'] = [analyzer.polarity_scores(v)['neg'] for v in news_df['title'].apply(clean_html)]\r\n",
    "news_features_df['neu_t'] = [analyzer.polarity_scores(v)['neu'] for v in news_df['title'].apply(clean_html)]\r\n",
    "news_features_df['pos_t'] = [analyzer.polarity_scores(v)['pos'] for v in news_df['title'].apply(clean_html)]"
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "source": [
    "news_features_df = news_features_df.groupby(['date', 'symbol']).sum()"
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "source": [
    "news_features_df.to_csv('../Data/news_features.csv')"
   ],
   "outputs": [],
   "metadata": {}
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "source": [],
   "outputs": [],
   "metadata": {}
  }
 ],
 "metadata": {
  "orig_nbformat": 4,
  "language_info": {
   "name": "python",
   "version": "3.7.11",
   "mimetype": "text/x-python",
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "pygments_lexer": "ipython3",
   "nbconvert_exporter": "python",
   "file_extension": ".py"
  },
  "kernelspec": {
   "name": "python3",
   "display_name": "Python 3.7.11 64-bit ('machineLearning': conda)"
  },
  "interpreter": {
   "hash": "15d6f6cf85598009a90599770be6a6b7799a460854b6a0a49d07b2b60db6e76d"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}